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An abstract of thesis. Breast cancer is a heterogeneous disease that is clinically 
classified based on the expression of estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2). Associated with the poorest 
prognosis of all subtypes, triple negative breast cancer (TNBC) is defined as ER-/PR-
/HER2-; lacking these receptors, TNBCs are insensitive to effective targeted therapies 
and chemotherapy remains the mainstay of treatment. Recent research has shown that 
platinum chemotherapy agents are particularly active in TNBC, including a clinical trial 
that demonstrated single agent cisplatin alone can induce response in a subset of TNBC 
patients. However, identification of biomarkers is still needed to distinguish sensitive 
patients from resistant ones, whom may benefit from other forms of chemotherapy. 
Recent studies have revealed that cisplatin activates the c-Abl/TAp73 apoptotic 
pathway, specifically in TNBCs with p53 mutations (~60% of all TNBCs). Our lab has 
identified miR-510 to be overexpressed in human breast tissue samples, suggesting a 
role in breast cancer. Our lab has validated Prdx1 to be a direct target of miR-510. Prdx1 
has been shown to protect cells from cisplatin and also inhibit the tyrosine kinase c-Abl. 
Therefore we wanted to determine the efficacy of miR-510 as a biomarker of cisplatin 
sensitivity and elucidate the mechanism of this sensitivity.  
Drug cytotoxicity assays indicate that miR-510 positively correlates with cisplatin 
sensitivity in TNBC cell lines. Furthermore, inhibition of miR-510 causes sensitive TNBC 
cell lines to become more resistant, while overexpression of miR-510 restores sensitivity 
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in resistant TNBC cell lines in vitro. MicroRNAs are ideal biomarkers in cancer as they 
regulate many processes in cancer development and progression and are also stable in 
biological fluids. Analysis of samples from our in vivo study reveals a positive 
correlation of miR-510 levels in matched tumor and serum samples, suggesting that 
serum expression of miR-510 is indicative of its expression in tumor samples. Analysis 
of breast cancer patient serum samples demonstrates that varying levels of miR-510 can 
be detected in human samples as well. We then went on to explore the mechanism of 
miR-510 mediated cisplatin sensitivity. IHC analysis of in vivo tumors suggests that 
miR-510 mediated sensitivity may not be through decreased proliferation or increased 
cleaved-caspase 3 dependent apoptosis. Prdx1 IHC analysis, along with matched tumor 
miR-510 expression suggests that negative regulation of Prdx1 may play a role in miR-
510 mediated cisplatin sensitivity. The Prdx1 rescue experiments found that the 
mechanism of miR-510 mediated sensitivity is dependent upon the negative regulation 
of Prdx1. Our mechanistic studies reveal that cisplatin treatment leads to upregulation 
and increased phosphorylation of TAp73 in miR-510 overexpressing cells. In cells 
overexpressing miR-510, we also show that cisplatin leads to dissociation of TAp73 from 
its repressor ∆Np63 and induction of downstream pro-apoptotic genes, PUMA and 
NOXA. Cumulatively, our data demonstrates that miR-510 is a potential, non-invasive 
biomarker of cisplatin sensitivity in TNBC. We also show this mechanism of sensitivity 
is attributed to, at least in part, the negative regulation of Prdx1 and the subsequent 
activation of TAp73 apoptotic pathway.   
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Introduction and Background  
Breast Cancer 
 Breast cancer is a heterogeneous disease that originates from tissues of the 
breast. Consisting of glandular, adipose and connective tissue, the breast functions to 
produce, store and release milk during lactation [1]. The most common types of 
malignancies are carcinomas that arise from the epithelial cells of milk producing 
lobules or milk transporting ducts (Figure 1). Soft tissue sarcomas may also develop in 
the breast, although they are rare [2]. Several risk factors are well known to contribute to 
the development of breast cancer, including personal and hereditary factors that are not 
modifiable and also lifestyle factors. Non-modifiable factors include age and family 
history of breast cancer. Advance age (65+ years) is one of the highest risk factor for 
breast cancer as risk increases across all ages until the age of 80 [3]. Family history of 
breast cancer is important as well. Women with a first degree relative with breast cancer 
have a higher risk of developing the disease; this risk increases significantly with each 
additional relative with breast cancer [3]. A small portion of breast cancer (5%-10%) is 
due to inherited mutations, most notably the breast cancer susceptibility genes BRCA1 
and BRCA2. Other non-modifiable factors could also increase the risk, including: benign 
breast disease, increased breast density, high endogenous hormone levels, early 
menarche and late age pregnancy [3]. Lifestyle-related factors could also add to the risk 
of breast cancer. Use of post-menopause hormone replacement therapy is well 
established to increase the risk of developing and dying from the disease [3]. Studies 
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have suggested that obese women and women that do not exercise regularly are at a 
higher risk of post-menopausal breast cancer than lean and active women [3, 4]. Women 
who are frequently exposed to alcohol, tobacco, radiation and various chemical 
pollutants are at a higher risk to have breast cancer [3]. With countless risk factors, it is 
not surprising that breast cancer is one of the most prevalent diseases of women in the 
United States and worldwide. It is estimated in the United States, there will be 231,840 
new cases of invasive breast cancer in 2015, along with 60,290 cases of in situ breast 
cancer. This disease is also projected to claim the lives of 40,290 women in the same year 
[5]. 
Figure 1. Breast anatomy showing the glandular structure, a complex system of 
lobules and ducts. Most breast cancers originate from epithelial cells of these 
lobules and ducts. Illustrations of lobular carcinoma in situ and ductal 
carcinoma in situ are also shown. Figure adapted from “Breast Cancer 
Treatment” 2015, National Cancer Institute PDQ®. Copyright 2011 by Terese 




Diagnosis: Breast cancer is usually suspected after detection of a mass during clinical 
breast examinations or mammograms, and occasionally through breast MRI. Biopsies 
are then taken to further distinguish between benign and malignant lesions [3]. Due to 
the extremely heterogeneous nature of breast cancer, it can be classified in a variety of 
ways. A common classification is by histopathology, first distinguishing in situ/invasive 
tumors and then classifying them into distinct subtypes based on their architectural 
features and growth patterns [2, 6]. In situ tumors are a noninvasive form of breast 
cancers that have not yet infiltrated beyond the original cell layer, most commonly 
ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) (Figure 1). While 
most of these tumors are not life-threatening, studies suggest that approximately one-
third of these cases will become invasive and may require intervention [7]. The majority 
of breast cancer cases are invasive, characterized by tumor cells that have penetrated 
into the surrounding breast tissue. Following diagnosis of invasive breast cancer, tumors 
are further classified by grade and stage to determine prognosis and guide treatment 
choice. TNM classification is commonly used to stage the tumor based on tumor size (T), 
spread to local lymph nodes (N) and whether the tumor has metastasized (M). Tumors 
are then assigned a stage of 0, I, II, III or IV, with increasingly poorer prognosis [2]. 
Grade is determined based on differentiation of the breast tumor (presence of ductal 
structure and nuclear pleomorphism), along with its proliferation rate (mitotic count). A 
grade of 1, 2 or 3 is assigned, where grade 1 is well differentiated with low proliferation 
rate and grade 3 is poorly differentiated with high proliferation. A higher grade 
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correlates with a poorer prognosis [8]. A pathologist will also determine the receptor 
status of the tumor, by immunohistochemistry (IHC) or fluorescence in situ 
hybridization (FISH), for the presence of estrogen receptor (ER), progesterone receptor 
(PR) and the amplification of human epidermal growth receptor 2 (HER2). This 
determines the treatment of the cancer, as there are highly effective, targeted therapies 
for tumors that express these receptors [2]. Various studies have shown that breast 
cancer can be defined by its molecular profile and classified into intrinsic subtypes: 
luminal A, luminal B, HER2 enriched, basal-like, claudin-low and normal-like [6, 9-11]. 
This new form of classification could allow for better differentiation of subtypes of 
breast cancer once thought to be similar, providing more specific information regarding 
prognosis and predicted response to treatments. However, this classification is currently 
limited to research as the cost of large scale microarray analysis and genome sequencing 
to classify breast cancers is not suitable for routine clinical analysis [6, 11, 12]. Current 
methodologies to assign molecular subtype of breast cancer are also not standardized as 
various methods of classification have been developed, some of which are still being 
improved upon [11, 13]. Current methods also requires the gene expression data of 
individual test tumors to be compared against a large, heterogeneous reference tumor 
set [13]. Therefore, classification of tumors into a molecular subtype is highly dependent 
on the reference set used in the classification method. These issues must be addressed 




Treatment Options: After diagnosis, breast cancer can be treated with an assortment of 
interventions. Current treatments include surgery, radiation, chemotherapy, hormonal 
therapy, and HER2-targeted therapies; either individually or in combination [3]. 
Surgeries are performed to remove the primary tumor with either breast-conserving 
lumpectomy or mastectomy. Radiation therapy is typically administered to lumpectomy 
patients and patients with a high risk of recurrence. Systemic treatments, hormonal 
therapies, targeted therapies and chemotherapies, can be administered prior to surgery 
(neoadjuvant) or after surgery (adjuvant). Tumors that are ER and PR positive are 
treated with tamoxifen, a Selective Estrogen Receptor Modulator (SERMs) that blocks 
estrogen signaling through the ER. For post-menopausal women, aromatase inhibitors, 
anastrozole and letrozole, are used to inhibit estrogen production through the 
aromatization of androgens. Patients with HER2 amplifications are treated with targeted 
therapies (trastuzumab, lapatinib and pertuzumab) that inhibit the HER2 signaling 
pathway. Chemotherapy is another systemic treatment with drugs that stop the growth 
of cancer cells and could be given in addition to targeted therapies. Most commonly 
used chemotherapies are anthracyclines, taxanes, antimetabolites, and alkylating agents. 
Survival rates are promising for early stage breast cancer. The five-year survival 
for localized and regional diseases is extremely high, 99% and 84% respectively. But 
once it has progressed into metastatic breast cancer, the survival rate drops drastically to 
24% [3]. Breast cancer is very treatable if detected at an early stage, when treatments are 
the most effective and a cure is more likely [14]. Therefore, there is an emphasis on early 
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detection and selecting the most effective intervention to prevent progression into late-
stage disease.   
 
Triple Negative Breast Cancer 
When classifying breast tumors based on receptor status, triple negative breast 
cancer (TNBC) encompasses a group of tumors that lack ER, PR and 
overexpression/amplification of HER2 [15]. Accounting for approximately 10-20% of all 
invasive breast cancer cases, TNBC is known to have the poorest prognosis of all the 
receptor-based subtypes [16]. This is evident as the 5 and 10 year survival percentages 
are the lowest of all the subtypes, independent of the stage at diagnosis (Figure 2) [17]. 
This poor prognosis can be attributed to higher rates of distant recurrence, shorter 
median time from relapse till death, and higher incidences of early visceral and central 
nervous system metastasis compared to other subtypes [18-20]. TNBCs are more 
commonly observed in younger women, as the average age of diagnosis is 5-10 years 
younger compared to non-TNBC [21]. There are multiple reports of higher rates of 
TNBC in women of African ancestry, with studies showing two-fold to three-fold higher 
frequency of TNBC in African American women compared to Caucasian American 
women [21, 22]. Studies have also suggests TNBC incidences are higher among women 
of Hispanic ancestry and women of lower socioeconomic status [23, 24]. A lower 
percentage of TNBC are discovered by mammograms as it is underutilized by younger 
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women or women of low socioeconomic status [23] and TNBCs are more likely 
mammographically occult due to lower tumor calcification [21].  
 
Treatment of TNBC: TNBC are more difficult to treat as they are generally more 
biologically aggressive [15] and the lack of hormonal receptors and HER2 renders them 
unresponsive to effective targeted therapies that are clinically available [25]. The current 
standard of care for TNBC is combination cytotoxic chemotherapy, since TNBC patients 
treated with chemotherapy showed higher response rate than non-TNBC patients in 
neoadjuvant, adjuvant and metastatic settings [26, 27]. A paradox of TNBC is that even 
with the increased sensitivity to chemotherapy, its survival rates remain lower than 
other subtypes [16, 25]. While TNBC patients respond well to anthracycline and taxane 
based regimens, there is still a high risk of relapse for patients with residual disease [15, 
28]. Since TNBC shows decrease duration of response from each successive line of 
chemotherapy [27], it is crucial to find the most effective first-line treatment to prevent 
drug resistance and disease progression. Therefore, current TNBC research focuses on 
novel biomarkers of response to treatment along with the development of effective, 
targeted therapies for TNBC. Potential TNBC targets under investigation include: 
preventing angiogenesis (e.g. anti-VEGF antibody), inhibiting growth factor pathway 
(e.g. EGFR inhibitors and mTOR inhibitors), and exploiting aberrant DNA repair 



















Figure 2.  Prognosis of breast cancer subtypes, by stage, shown as percentage 
of overall survival for 5 and 10 years. Figure adapted from “SnapShot: Breast 
Cancer” by K. Polyak and O.M. Filho, 2012, Cancer Cell, 22, pg. 562. 






TNBC is often used as a surrogate term for basal-like breast cancer and BRCA1 
associated breast cancer due to similarities between the groups. While TNBC and basal-
like breast cancer are often used synonymously due to the large overlap between the 
two groups, studies found around 30% discordance between the two groups [29]. TNBC 
is distinguished solely by clinical assessment of receptors (ER, PR, and HER2) and not 
all TNBCs exhibit the molecular profile of basal-like breast cancer. Basal-like breast 
cancer is based on its molecular profile (e.g. CK 5/6, c-kit, HER1, and others) and not all 
basal-like breast cancers display the triple negative phenotype [15]. TNBC are also often 
associated with BRCA1 associated breast cancers since BRCA1 mutation carriers that 
develop breast cancer are often triple negative for ER, PR, and HER2 [30]. However, 
there are discordances between these two groups as well since majority of TNBCs are 
sporadic and does not harbor BRCA1 mutation. The large overlap between TNBC and 
basal-like/BRCA1 associated breast cancers suggest TNBC may be sensitive to similar 
therapeutics. BRCA1 mutation carriers and many sporadic basal-like breast cancers have 
altered (e.g. promoter methylation and decrease transcript levels) or loss of BRCA1 
activity [31], which is involved in homologous recombination to repair double strand 
breaks in DNA. The aberrant DNA repair mechanisms of BRCA1 associated/basal-like 
breast cancer renders them vulnerable to platinum agents (generates double strand 
breaks) leading to tumor cell apoptosis [31]. Various in vitro and in vivo studies have 
demonstrated that BRCA1 associated and basal-like breast cancer were significantly 
more sensitive to cisplatin compared to other popular chemotherapies [32, 33]. A recent 
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randomized, phase III trial (NCT00532727) found that TNBC patients with mutant 
BRCA1/2 achieved an objective response rate of 68%, treated with a platinum agent 
(carboplatin), compared to 33% when treated with a taxane (docetaxel); whereas, these 
differences in response rate were not observed in non-mutant BRCA1/2 patients. This 
trial has also found that progression free survival (PSF) was longer in mutant BRCA1/2 
breast cancer patients, treated with platinum agents compared to taxane agents. 
Promising trials, like NCT00532727, have sparked a renewed interest in treating TNBC 
with platinum agents due to the similarities of between TNBC and basal-like/BRCA1 
associated breast cancer.  
  
Platinum Agents: Platinum agents are a group of “alkylating-like” chemotherapy agents 
that are composed of platinum complexes. The first platinum agent, cisplatin or cis-
diamminedichloroplatinum(II), was introduced in the clinics in 1970’s and has made 
significant impact in treating cancer, particularly germ cell cancers (testicular and 
ovarian) [34]. Cisplatin is still widely used in the clinics to treat various solid tumors 
including: head and neck, bladder, cervical and small cell lung cancer [35]. The severe 
side effects of cisplatin (nephrotoxicity and neurotoxicity) initiated platinum drug 
development, leading to carboplatin and subsequently, oxaliplatin to combat 
mechanisms of drug resistance [34]. These are the three main platinum agents that are 
widely used in treating cancer (Figure 3). Oxaliplatin has a distinct structure compared 
to cisplatin and carboplatin, leading to activation of different pathways upon DNA 
damage; this is further supported by the fact that cisplatin-resistance cells response to 
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oxaliplatin [34, 36]. Due to its differential mechanism of action, oxaliplatin is only 
approved for the treatment of colorectal cancer. Carboplatin is used to treat similar types 
of cancers as cisplatin, as their mechanism of action are similar. Carboplatin offer a 
similar level of clinical activity as cisplatin, while eliminating the severe side effects [35, 
36]. However, studies has shown that carboplatin is less potent than cisplatin, 
demonstrated by significantly higher dosage to match the effectiveness of cisplatin and 
slower rate of DNA adduct formation [35, 36]. Upon uptake into the cell by copper 
transporter-1 (CTR1), cisplatin become activated [34-36]. While cisplatin could interact 
with various cellular molecules, deoxyribonucleic acids (DNA) remains the primary 
target. Cisplatin then covalently bonds to the N7 position of the imidazole ring of purine 
bases (mostly guanine) to generate, predominately 1,2 intrastrand and 1,3 intrastrand 
cisplatin-DNA adducts (Figure 3) [34-36]. A complex system of molecular pathways has 
been shown to be activated upon recognition of cisplatin-DNA adducts (Figure 4). The 
various pathways are involved in promoting G2 cell cycle arrest (ATM/ATR), attempt to 
repair DNA damage (either via nucleotide excision repair/NER or mismatch repair 
system/MMS), and activation of survival/apoptotic pathways depending on extent of 
DNA damage [34-36]. The tumor suppressor p53 plays an important role downstream of 
cisplatin-induced DNA damage, promoting cell cycle arrest, NER machinery, and 
apoptosis [34-36]. However, p53 is often mutated in many types of cancers, including 
TNBC [17, 36, 37]. Various studies have shown that wild-type p53 correlates with 
cisplatin sensitivity [37]. However, cisplatin can still induce apoptosis in the presence of 
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p53 mutation by activation of c-Abl through the MMR system [35]. A mechanism of 
cisplatin-induced cell death specifically in TNBC has also been uncovered (Figure 5) 
[38]. It has been shown that tumor suppressor, p53 family members, Np63 and TAp73, 
are coexpressed in a subset of TNBC that has a mutational inactivation of p53 
(significantly higher in TNBC compared to non-TNBC subtypes, 54% vs 26% [17]). In 
TNBC tumors, Np63 acts a survival factor by binding to TAp73 and inhibiting it from 
promoting apoptosis. Upon cisplatin induced DNA damage, c-Abl (non-receptor 
tyrosine kinase) becomes activated and phosphorylates TAp73, allowing dissociation of 
its repressor Np63; thus allowing TAp73 to transcribe pro-apoptotic genes leading to 
tumor cell death (Figure 5). As this molecular pathway is only responsive to cisplatin 
treatment and no other chemotherapeutic agents (taxanes and anthracyclines), 
coexpression of Np63/TAp73 is being investigated as a potential biomarker of cisplatin 














 Figure 3.  Chemical structures of platinum-based chemotherapy drugs: cisplatin, carboplatin, 
and oxaliplatin. Also included, cisplatin mechanism of action. Figure adapted from “Cellular 
Processing of Platinum Anticancer Drugs” by D. Wang and S.J. Lippard, 2005, Nature Reviews 








Figure 4.  Downstream molecular mechanism of cisplatin induced DNA 
damage. Figure adapted from “Cisplatin in cancer therapy: Molecular 
mechanisms of action” by S. Dasari and P.B. Tchounwou, 2014, 
European Journal of Pharmacology, 740, pg. 370. Copyright 2014 by 




















Figure 5: Mechanism of cisplatin induced cell death in TNBC. Figure adapted from 
“Triple Negative Breast Cancer: Role of Specific Chemotherapy Agents” by S.J. 
Isakoff, 2010, Cancer J, 16, pg. 59. Copyright 2010 by Lippincott Williams & Wilkins, 








Promising pre-clinical data led to clinical trials to investigate the potential of 
platinum agents in TNBC. Various clinical investigations of platinum agents in TNBC 
offered mixed results; although many studies investigated platinum doublet or triplet 
regimens (in combination with other chemotherapies) and often use carboplatin, which 
may be less potent than cisplatin [35, 39]. A retrospective study showed a higher 
complete response rate with neoadjuvant, cisplatin based chemotherapy in TNBC 
patients (88%) vs non-TNBC patients (51%) [40]. Similarly, metastatic TNBC patients 
also showed higher response rates to cisplatin based chemotherapy compared to other 
breast cancer subtypes [40, 41]. Many previous trials do not provide a clear assessment 
of the efficacy of platinum drugs in treating TNBC due to: limited number of trials since 
cisplatin is not a standard of care in treating TNBC, analysis of retrospective samples 
that lack HER2 data (prior to the discovery of HER2), investigation of platinum agents in 
polychemotherapy regimens, and administration of platinum as a non-first line therapy. 
A phase II clinical trial (NCT00148694) addressed these problems and evaluated the 
efficacy of neoadjuvant, single-agent cisplatin as first line chemotherapy to newly 
diagnosed TNBC patients. The results show a pathologic complete response (pCR) in 
22% patients while 36% showed complete or near-complete responses [42]. Due to the 
low sample numbers (28 patients) and the relatively low pCR rate compared to other 
polychemotherapy regimens used to treat TNBC, the data do not justify using 
neoadjuvant, single agent cisplatin to treat all TNBC cases [42]. However, it indicates 
that cisplatin is particularly active in a subset of TNBC cases and suggests the need of 
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biomarkers to identify responsive patients [27]. This trial evaluated various potential 
markers including altered BRCA1 activities (Figure 6). While the two patients with 
BRCA1 mutations responded extremely well and reached pCR, the majority of the 
patients who showed complete or near-complete response did not harbor the mutation. 
Low BRCA1 mRNA levels and BRCA1 promoter methylation are also inconsistent 
predictors [42]. The aforementioned biomarker, Np63/TAp73, was also assessed as 
these proteins are involved in a molecular pathway by which cisplatin induces apoptosis 
specifically in TNBC [38]. Of the patients that were positive for Np63/TAp73, 33% (3/9) 
achieved pCR; whereas only one of thirteen, that were negative for the biomarker, 
reached pCR [42]. This biomarker was further evaluated in a phase II clinical trial 
(NCT00483223) in metastatic TNBC and did not proved to be a successful biomarker of 
cisplatin sensitivity in this setting [27, 43]. Data from these trials suggests that there is 























Figure 6.  Potential biomarkers of cisplatin sensitivity. Assessment of potential biomarkers 
of cisplatin sensitivity in TNBC in the phase II clinical trial NCT00148694. Black dots 
indicate presence of marker, while samples with no data are indicated by gray X. Figure 
adapted from “Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer” by D.P 
Silver, 2010, Journal of Clinical Oncology, 28, pg. 1148. Copyright 2010 by American Society 






Initially discovered in C. elegans, microRNAs (miRNAs) have been one of the 
most extensively studied molecules in their role of post-transcriptional gene regulation 
[44]. miRNAs are a class of endogenous, short non-coding RNAs (~18-24 nucleotides) 
that serve as negative regulators of gene expression by targeting specific mRNAs [45]. 
The majority of miRNAs are intergenic and are transcribed as primary miRNA (pri-
miRNA) transcripts by RNA polymerase II. In other cases, miRNAs are intragenic, 
existing within introns of protein coding or non-protein coding genes and must be 
excised by the splicing machinery [45]. While in the nucleus, pri-miRNAs are processed 
by the enzyme Drosha to form precursor miRNA (pre-miRNA) hairpin structures 
(Figure 7). These pre-miRNAs are then actively transported to the cytosol and further 
processed by the Dicer enzyme, resulting in a double strand miRNA duplex [45]. As the 
duplex is separated, the complementary strand is degraded and the mature miRNA 
strand loaded into a multi-protein complex known as the RNA-induced silencing 
complex (RISC) by associating with the Argonaute (AGO) protein. miRNAs then bind 
target transcripts through base-pair complementarity of the seed sequence (6-8 nt) at the 
3’ UTR (untranslated region) of the mRNA. This miRNA-RISC complex can then 
negatively regulate target transcripts through translational repression or transcript 
degradation through endonucleolytic cleavage (requires perfect complementarity of 
seed sequence) [45-47]. Due to the small region of complementarity needed for miRNA 
regulation, a single mRNA may be targeted by multiple miRNAs and a single miRNA 
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may target multiple transcripts, adding to their complexity. To date, over 1800 human 
miRNAs sequences have been identified (mirbase.org) and are predicted to regulate a 





Figure 7. Biogenesis and post-transcriptional regulation of miRNAs. Figure adapted 
from “MicroRNAs: Small RNAs with a Big Role in Gene Regulation” by L. He and G.j. 
Hannon, 2004, Nature Review Genetics, 5, pg. 524. Copyright 2004 by Nature 




The role of miRNAs have been characterized in various biological processes, 
including development, differentiation, apoptosis, and proliferation [49]. Accumulating 
evidence from studies suggest deregulation of miRNA is involved in tumor initiation 
and progression; one study found 72.8% of breast cancers showed miRNA gene number 
abnormality [50]. Considered by many to be a new class of oncogenes and tumor 
suppressors, miRNA promote tumorigenesis through negative regulation of genes 
involved in functions such as cell cycle regulation and apoptosis; and also suppress cell 
growth by targeting genes involved in proliferation and survival [51]. This has led to 
extensive research on exploring miRNAs as possible therapeutic targets in breast cancer. 
An example is the clinical trial NCT01829971, a phase I clinical trial to test the efficacy of 
MRX34, a miR-34 mimic, to treat liver cancer. Due to its involvement in a variety of 
breast cancer processes, miRNAs have also garnered attention as potential biomarkers of 
diagnosis, prognosis, and even treatment choice. Due to their small size, miRNAs have 
been found to be extremely stable and reproducibly detected in various biological fluids 
including serum and plasma [52]; carried in primarily in exosomes that could also be 
involved in paracrine and endocrine cell-cell communications [53].  
miR-510: The miRNA of interests in this study is miR-510 (Figure 8), a miR-506 family 
member that is located in the intergenic region of chromosome Xq27.3; a region that has 
been shown to be amplified in breast cancer [54]. Tissue specificity analysis of miR-510 
reveals significant overexpression of miR-510 in the testes [55]; interestingly, cisplatin 
has been used to successfully treat testicular cancer [34]. As a poorly conserved miRNA, 
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there has been limited research on miR-510. Studies have shown that miR-510 regulates 
serotonin receptors and may play a role in irritable bowel syndrome [56, 57]. Studies 
have also suggests miR-510 may play a role in various cancers, including lung cancer, 
gastric cancer, ovarian cancer, and lymphoblastic and myeloid leukemias [58-62]. The 
role of miR-510 in breast cancer was first established by Findlay et al, showing that miR-
510 repressed the tumor suppressor protein PDEF in breast cancer [63]. The miR-510 
mediated loss of PDEF protein expression in non-invasive breast cancer cells led to the 
progression into a more invasive phenotype [63]. Our lab then went on further to 
investigate the role of miR-510 in breast cancer [63, 64]. We have shown that miR-510 
overexpression in human breast tissue samples compared to matched non-tumor 
samples, suggesting a role in breast cancer (Figure 9) [63]. We have also found miR-510 
to be an oncogenic miRNA, promoting proliferation, migration, invasion and colony 
formation in breast cancer [64]. Our lab has also identified peroxiredoxin 1 (Prdx1) as a 
novel target of miR-510. Luciferase assays were conducted in MDA-MB-231 cells stably 
infected with miR_510 or scrambled controls and transiently transfected with luciferase 
reporter vector (empty vector; EV), vector with PRDX1 3’UTR, or vector with PRDX1 
3’UTR mutated at the miR-510 seed site (PRDX mut) (Figure 10). The assay showed that 
an increased repression of the PRDX1 3’UTR when miR-510 was overexpressed 
compared to scrambled controls. However, there is no significant decrease in luciferase 
activity with the EV control and the PRDX mut constructs, in the presence of miR-510, 
suggest that miR-510 directly binds to the predicted site within the 3’UTR of Prdx1; this 
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luciferase assay and the downregulation of Prdx1 protein expression provides evidence 
that Prdx1 is a direct target of miR-510 [64]. More studies are required to further uncover 

















Figure 8. Predicted secondary structure of pre-miR-510 using plt22gif 
program (mfold program) developed by D. Stewart and M. Zuker.  
Sequence of mature miR-510 highlighted in red. Figure adapted from 
“miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes” 
by S.D. Hsu, 2008, Nucleic Acids Research, 36. Copyright 2007 by 






      
Figure 9. Quantitative real-time PCR assessing normalized miR-510 
expression in human breast tumors (grey bars) compared to matched 
non-tumor samples (black bars). Fold differences of miR-510 in 
matched tumor vs. normal tissue: #1335-33.7, #1412-15.7, #1420-
30884.0, #1844-45.0, #1968-32.6. Figure adapted from “MicroRNA-
mediated inhibition of prostate-derived Ets factor messenger RNA 
translation affects prostate-derived Ets factor regulatory networks in 
human breast cancer.” By V. Findlay, 2008, Cancer Research, 68, pg. 
8505. Copyright 2008 by American Association for Cancer Research. 
Adapted with permission. [63] 
















 Figure 10. Luciferase assay in MDA-MB-231 cells stably 
transfected with scrambled control (dark grey) or miR-510 (light 
grey) transiently transfected with pGL3 promoter luciferase 
reporter vector alone (EV), the PRDX1 3’UTR reporter construct 
or the PRDX1 3’UTR reporter construct mutated at miR-510 
seed sequence. Figure adapted from “MicroRNA-510 promoted 
cell and tumor growth by targeting peroxiredoxin1 in breast 
cancer” by Q.J. Guo, 2013, Breast Cancer Research, 15:R70, pg. 9. 
Copyright 2013 by Guo et al., licensee BioMed Central Ltd. 







Peroxiredoxin 1: Prdx1 is a thiol-specific antioxidant enzyme which protect cells from 
oxidative damage by reducing cellular ROS (H2O2 and O2-), RNS (peroxynitrite), and 
thiyl radicals [65]. Aside from its enzymatic activities, Prdx1 has been shown to be 
interact with various proteins involved in regulation of cell signaling, proliferation and 
apoptosis [65, 66]. Prdx1 has also been shown to act as a chaperone protein by binding to 
transcription factors (NF-ĸB and c-Myc) and modulate gene expression in the nucleus 
[65]. Studies have demonstrated that Prdx1 protects cells from ionizing, ultraviolet 
radiation [67, 68], and cisplatin induced cell death [69]. Interestingly, Prdx1 has been 
shown in many studies to be a physiological inhibitor of c-Abl by binding to its SH3 
domain, preventing it from being phosphorylated and hindering its kinase activity [69-
71]. Therefore protective role Prdx1 plays against cisplatin may be due to its suppression 










Hypothesis: Elevated miR-510 expression is a predictive indicator of response to 
cisplatin in triple negative breast cancer (TNBC). miR-510 mediated, cisplatin-induced 





















Specific Aim 1 
Rationale 
Treating TNBC remains a clinical challenge as it is not responsive to some of the 
most effective breast cancer therapeutics. Due to similarities between TNBC and BRCA1 
associated breast cancer/basal like breast cancer, it was hypothesized that the aberrant 
DNA repair mechanism of TNBC could be exploited by DNA damaging therapeutics 
such as platinum chemotherapy agents. As this investigation progressed into clinical 
trials, it was determine that only a subset of TNBC patients responded to single agent 
cisplatin. Assessment of various biomarkers of cisplatin sensitivity proved to be 
unsuccessful, suggesting a need for better biomarkers to distinguish responsive patients 
to improve treatment outcome in TNBC. Prdx1 has been show to play a protective role 
against cisplatin induced cell death and our lab has validated Prdx1 as a direct target of 
miR-510. This suggests that miR-510 may be a potential biomarker of cisplatin sensitivity 
in TNBC. MicroRNAs has gained attention as potential biomarkers since dysregulation 
of miRNAs are known to be involved in many cancer processes. Along with their 
stability in many biological fluids, miRNAs are ideal non-invasive biomarkers of 
prognosis, diagnosis, and treatment response in cancer. The goal of this aim is to explore 




Specific Aim 1: Determine if elevated miR-510 expression correlates with cisplatin 
sensitivity in TNBC 
Task 1: Assess cisplatin cytotoxicity in various TNBC cell lines in vitro to 
determine: 
1. If a correlation exists between cisplatin sensitivity and miR-510 
expression 
2. If gain of miR-510 expression sensitize resistant cell lines to cisplatin  
3. If loss of miR-510 expression makes sensitive cell lines more resistant 
to cisplatin  
Task 2: Measure miR-510 levels in mouse and human serum samples to define: 
1. If miR-510 could be detected in serum samples  











Cell culture: MDA-MB-231 and BT549 cell lines were a gift from Dr. Dennis Watson at 
the Medical University of South Carolina. SUM149 and SUM159 cell lines were a gift 
from Dr. Steve Ethier at the Medical University of South Carolina. MDA-MB-231 and 
BT549 cell lines were cultured in a 37°C, 5% CO2 incubator and SUM149 and SUM 159 
cell lines were cultured in a 37°C, 10% CO2 incubator, all in their respective media. 
MDA-MB-231 cells were incubated in DMEM/High Glucose media (HyClone, South 
Logan, UT), with 10% fetal bovine serum (FBS) (HyClone, South Logan, UT) and 1% 
Penicillin/Streptomycin mixture (Fisher Scientific, Hampton, NH).  BT549 cells were 
incubated in RPMI 1640 media (HyClone, South Logan, UT) with 10% FBS (HyClone, 
South Logan, UT) and 1% Penicillin/Streptomycin mixture (Fisher Scientific, Hampton, 
NH). SUM149 and SUM159 cell lines were incubated in Ham’s F-12 media (HyClone, 
South Logan, UT), with 5% FBS (HyClone, South Logan, UT) and the following 
additives (Fisher Scientific, Hampton, NH): Insulin (5µg/ml), hydrocortisone (1µg/ml), 
amphotericin B (2.5µg/ml) and gentamicin (25µg/ml). Media on the cells were changed 
every 2-3 days and cells are passaged by using 0.05% trypsin (HyClone, South Logan, 
UT) when plates were ≤90% confluent.  
Cisplatin cytotoxicity screen: TNBC cell lines (MDA-MB-231, BT549, SUM149 and 
SUM159) were plated at a density of 2.5x103 cells/100L into a 96 well plate. After 24 
hours in culture conditions, the cells were treated with a range of cisplatin (MUSC 
Pharmacy, Charleston, SC) concentrations (0, 1, 3, 10, 30, 100, 300 and 1000µM) in 
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triplicates. Cells were left in culture for an additional 72 hours. After 72 hours, each well 
was fixed with 50µL of cold 5% trichloroacetic acid (TCA) for an hour at 4°C and then 
washed four times with distilled water. The wells were further stained by adding 75µl of 
sulforhodamine B (SRB) reagent (0.4% SRB in 1% acetic acid), incubated at 25C for an 
hour and washed four times with 1% acetic acid. Next, the SRB was solubilized with 100 
µl of 10mM unbuffered Tris Base solution, while shaking for 5 minutes on a shaker 
platform.  The plate was then read in a 96-well plate reader (µQuantTM, Bio-Tek, 
Winooski, VT) with the working wavelength 540nm. The optical density of each well 
was normalized to the untreated wells of each respective cell line, expressed as percent 
viability and plotted against cisplatin concentration. The sensitivity of cell lines were 
assessed by IC50 value, the concentration of cisplatin required to reach 50% viability, 
calculated by GraphPad. Each cell sample was collected and processed for RNA analysis 
(see below). A Pearson’s Correlation test was used to determine the correlation of miR-
510 expression and cisplatin sensitivity (IC50 cisplatin concentration) in TNBC cell lines.   
Generation of stable cells: MDA-MB-231 cells were plated at a density of 5.0x104 
cells/well in a 24 well plate with 500µl of cell specific media with 5% heat inactivated 
FBS. After 24 hours in culture, a virus suspension of 2µl of Scr or miR-510 virus particles 
(Genecopoeia, Rockville, MD) diluted in complete media with Polybrene (8mg/ml) 
(Santa Cruz, Dallas, TX) was prepared for each well. The cells were infected by 
removing the old culture media and replacing with virus suspension and left overnight. 
The cells were then trypsinized and re-seeded in 6 well plates and incubated for 48 
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hours in regular media. Stably transduced cells were selected by replacing old media 
with new media containing hygromycin (Fisher, Hampton, NH) at 500µl/ml for SCR 
cells and puromycin (Fisher, Hampton, NH)  at 0.15µg/ml for miR-510 cells. New 
selections media was added every 3 days until drug resistant colonies become visible by 
fluorescence microscopy.     
In vitro mir-510 GOF and LOF: For the gain-of-function (GOF) studies, MDA-MB-231 
cells stably infected with Scr or miR-510 lentivirus were plated at a density of 2.0x105 
cells/well in a 6 well plate. After 24 hours in culture, the cells were treated with 
increasing concentrations of cisplatin (0, 3 and 10M) for another 24 hours. Cell viability 
was assessed by Trypan blue exclusion assay using the CelloMeter counter (Nexcelom, 
Lawrence, MA). Cell viability was measured as a percentage of viable cells compared to 
untreated wells of respective cell line. Each treatment was measured in triplicate. Cell 
samples were collected and processed for both protein and RNA (see below). 
For the loss-of-function (LOF) studies, BT549 cells were plated at a density of 2.0x105 
cells/well in a 6 well plate. After 24 hours in culture, cells were transfected with either 
1g of pEZx Scr vector (control) or 1g of pEZx anti-miR-510 (miR-510 inhibitor) vector 
using the XTREME Gene regent plasmid protocol (Roche, Nutley, NJ). After 48 hours, 
the cells were treated with increasing concentrations of cisplatin (0, 3 and 10M) for 24 
hours. Cell viability was assessed by Trypan blue exclusion assay as described above. 
Cell viability was measured as a percentage of viable cells compared to untreated wells. 
Each treatment was measured in triplicate.  
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RNA extraction and quantitative Real-Time PCR analysis: RNA was extracted using 
RNeasy Plus Mini kit (Qiagen, Valencia, CA). For miRNA analysis, 100ng of total RNA 
was reverse transcribed into complementary DNA (cDNA) with miR-510 specific 
primers using TaqMan Reverse Transcription kit (Applied Biosystems, Grand Island, 
NY) as per manufacturer’s instructions. Quantitative real time PCR (qPCR) was then 
performed using 1l of reverse transcribed cDNA, 0.5l of TaqMan miR-510 probe 
(Applied Biosystems, Grand Island, NY), 5 µl qPCR master mix (BioRad, Hercules, CA) 
and 3.5l of nuclease-free water as per the manufacturer’s instruction on the LightCycler 
480 machine (Roche, Nutley, NJ). For mRNA analysis, 1g of total RNA was reverse 
transcribed into cDNA in a 20l reaction using the iScript Kit (BioRad, Hercules, CA). 
qPCR was then performed to assess PRDX1 and GAPDH (for normalization) transcript 
expression, using 2.5l of 1:20 dilution of reverse transcribed cDNA, 0.1l of 20µM 
forward gene primer, 0.1l of 20µM reverse gene primer, 0.1l of UPL probe (Roche, 
Nutley, NJ), 5l of qPCR master mix (BioRad, Hercules, CA) and 2.2l of nuclease-free 
water, using the universal probe library (UPL) system (Roche, Nutley, NJ) as per the 
manufacturer’s instructions on the LightCycler 480 machine (Roche, Nutley, NJ). Primer 
sequences and UPL probe for each gene are shown in Table 1. All samples were run in 
triplicates. The relative expression of each gene was quantified on the basis of Ct values 
in comparison to an internal standard curve for each gene using the software provided 








Table 1. Primers and probes used for qPCR. 
Gene 5’ primer sequence 3’ primer sequence UPL Probe  
GAPDH agccacatcgctcagacac gcccaatacgaccaaatcc 60 
TP73 ggagggacttcaacgaagg tcatccacatactgcgagaga 19 
PUMA ctgcctcaccttcatcagg gcagagcacaggattcacag 79 




Protein extraction and Western Blot analysis: Protein was extracted by lysis of cell 
pellets with RIPA buffer (50mM Tris, 150mM NaCl, 0.5% sodium deoxycholate, 1% 
Triton X 100 and protease inhibitor cocktail) and protein concentrations are determined 
by performing a BCA assay as per the manufacturers’ instructions (Pierce, Fisher 
Scientific, Hampton, NH). 25ug protein of each sample was then separated on an SDS-
PAGE gel and transferred to a PVDF membrane (Fisher Scientific, Hampton, NH) using 
the BioRad western blotting system (BioRad, Hercules, CA). Membranes were blocked 
with 10% milk in 1X Tris buffer saline-Tween (TBST) for 1 hour and then probed 
overnight, at 4°C with shaking, with Prdx1 (1:1000 dilution; Abcam, Cambridge, MA) 
and GAPDH (1:1000 dilution; Santa Cruz, Dallas, TX) antibodies. The membranes were 
then washed with 1X TBST and incubated with secondary antibodies (anti-rabbit, 1:2000; 
GE Healthcare, Piscataway, NJ) at 25°C for 45 minutes with shaking. Membranes were 
washed again with 1X TBST and before enhance chemilluminescence (ECL) solution was 
added for 5 minutes (Pierce, Fisher Scientific, Hampton, NH). Signals were detected 
using x-ray films (Phenix, Candler, NC) and SRX 101a film processor (Konica Minolta, 
Ramsey, NJ).  
miR-510 expression of murine tumors: Frozen tumors (stored at -80°C) from the in vivo 
study previously conducted in our lab (Figure 15) were placed in a mortar with liquid 
nitrogen and crushed into a powder-like consistency. RNA was then extracted from the 
samples using TRIzol® reagent (Invitrogen, Carlsbad, CA) as per the manufacturers’ 
instruction. RNA samples were cleaned with DNA-free Kit (Ambion, Grand Island, NY) 
36 
 
to remove genomic DNA. RNA concentration and quality were determined using a 
Nanodrop spectrophotometer. miR-510 was then reverse transcribed and levels assessed 
by qPCR as described above. Samples are normalized to GAPDH using the iScript kit 
and qPCR as described above.  
Murine serum miR-510 expression: Serum samples from each experimental mouse in the 
in vivo study (Figure 15) were assessed for miR-510 expression. 50uL of each serum 
sample was used for RNA extraction using TRIzol® LS reagent (Invitrogen, Carlsbad, 
CA) as per the manufacturers’ instructions. For miRNA analysis, 5L of extracted RNA 
was reverse transcribed using miR-510 specific primers using TaqMan Reverse 
Transcription kit (Applied Biosystems, Grand Island, NY) as previously described. The 
miR-510 levels was then assessed by qPCR as previously described.  
Human serum miR-510 expression: Serum samples from breast cancer patients were 
obtained from MUSC’s Tissue Biorepository. These serum samples were processed and 
assessed for miR-510 expression as described above.  
Correlation of murine tumor and serum miR-510 expression: A Pearson’s Correlation 
test was performed between the relative expression of miR-510 in mouse serum and 
tumor samples of the in vivo experiment (Figure 15) to determine the relationship 






Previous work in our lab has tested platinum sensitivity in the non-transformed breast 
cell line MCF10A that were stably infected with either a scramble (SCR) or miR-510 (510) 
lentivirus. Treatment with cisplatin revealed that MCF10A overexpressing miR-510 had 
a significant increase (~3.5 –fold) in sensitivity (IC50 values: SCR=10.2M vs 510=2.9M) 
compared to the scramble control cells (Figure 11). Treatment with carboplatin yielded 
similar results (IC50 values: SCR=24.3M vs 510=10.1M). While this result is promising, 
it will have to be explored in a TNBC setting. 
Cisplatin sensitivity correlates with miR-510 levels in TNBC cell lines. To determine 
the sensitivity of various TNBC cell lines to cisplatin, a cytotoxicity assay was performed 
with MDA-MB-231, BT549, SUM149 and SUM159 cells. Assessment of viability with a 
SRB assay reveals a broad range of sensitivity in TNBC cell lines. SUM149 cells showed 
the highest sensitivity with an IC50 of 0.76µM, followed by SUM159 (2.12 µM), BT549 
(7.24 µM) and MDA-MB-231 (11.6 µM) (Figure 12-A).  Next, miR-510 expression in these 
cell lines were assessed to determine if a correlation between miR-510 expression and 
cisplatin sensitivity exists. Analysis of miR-510 qPCR shows that SUM149 cell line 
expresses the highest level of miR-510, followed by SUM159, BT549 and MDA-MB-231 
(Figure 12-B). Plotting miR-510 expression of these cell lines against matched cisplatin 
IC50 values reveals a Pearson’s Correlation coefficient of -0.96 (Figure 12-C). This 
demonstrates a positive correlation between miR-510 expression and cisplatin sensitivity 







Figure 11. Cytotoxicity curve of the non-transformed MCF10A SCR & miR-510 
stable cells treated with increasing concentrations of cisplatin and carboplatin for 
72 hrs. IC50 values of cisplatin treatment are 10.2µM and 2.9µM for SCR and 510 
cells respectively. IC50 values of carboplatin treatment are 24.3µM and 10.1µM 





Figure 12. Cisplatin cytotoxicity curves of triple negative breast cancer cell lines treated with 
increasing concentrations of cisplatin for 72 hrs with IC50 values (A). Normalized, relative 
expression of miR-510 in various triple negative breast cancer cell lines though qPCR (B). 
Cisplatin sensitivity (IC50 values) plotted against matched miR-510 expression of each TNBC 




Overexpression of miR-510 sensitizes resistant MDA-MB-231 cells to cisplatin. Next, 
we wanted to determine if miR-510 expression could directly modulate sensitivity to 
cisplatin. In our GOF study, MDA-MB-231 SCR & miR-510 stables cells were treated 
with cisplatin to determine if overexpression of miR-510 is sufficient to sensitize a 
cisplatin-resistant cell line. Assessment of Trypan blue exclusion assay resulted in a 
statistically significant reduction in cell viability in the miR-510 overexpressing cells 
when compared to the SCR cells (Figure 13-A) when treated with cisplatin. Assessment 
of miR-510 by qPCR in these stable cells validates overexpression of miR-510 in the 510 
cells (Figure 13-B). Western blot analysis of these stable cells also validates negative 
regulation of Prdx1 protein expression by miR-510 (Figure 13-C).   
Inhibition of miR-510 causes sensitive BT549 cells to become more resistant to 
cisplatin. To further explore the role of miR-510 in modulating cisplatin sensitivity, we 
next performed a LOF study. BT549 cells were transfected with a SCR control vector or 
an anti-miR-510 vector and treated with cisplatin. Assessment of the Trypan blue 
exclusion assay reveals a statistically significant increase in cell viability in the anti-miR-









Figure 13. miR-510 GOF study in MDA-MB-231 cells. Viability of MDA-MB-231 SCR & 510 stably 
infected cells treated with increasing concentration of cisplatin for 24 hrs (A). Expression of miR-510 
in MDA-MB-231 SCR & 510 stable cells by qPCR (B). Expression of Prdx1 protein expression in MDA-





Figure 14. miR-510 LOF study in BT549 cells. Viability of BT549 cells transiently transfected 
with SCR or anti-510 vectors and treated with increasing cisplatin concentration for 24 hrs (A). 
Expression of Prdx1 protein expression in BT549 transiently transfected with SCR or anti-510 





Previous work in our lab has also tested miR-510 mediated cisplatin sensitivity in 
an in vivo model (Figure 15). Stables of the invasive, transformed breast MDA-MB-231 
(TNBC) cell lines were generated by infecting with either a scramble control (SCR) or 
miR-510 lentivirus. These cells were then orthotopically injected into the inguinal 
mammary fatpad of nude, female mice (group of n=24 per cell line). At week 1 (when 
tumor sizes were consistent for all groups) 12 mice from the SCR group were given 
intraperitoneal injection of 100L saline while the experimental group received 100L of 
1mg/ml cisplatin (human equivalent dose of cisplatin, 15mg/m2). The same treatment 
was administered to the miR-510 groups. The mice were treated twice weekly for a total 
of 4 weeks. Tumor volume was monitored throughout the study. Comparing the SCR 
and miR-510 groups treated with saline, the 510 tumors grew significantly faster and 
were larger at the end of the study when compared to the SCR controls; this is consistent 
with our previous work, supporting miR-510 as an oncogene that promotes tumor 
growth [63, 64]. The miR-510 mice treated with cisplatin resulted in a statistically 
significant reduction in tumor volume compared to the saline treated miR-510 mice; 
whereas no such difference was observed in the SCR groups (Figure 16). Assessment of 
the average tumor weights per group showed the same trend as the tumor volume 
(Figure 16).  
MicroRNAs are the ideal biomarkers due to their stability and can be non-
invasively detected in various biological fluids including serum [52]. Serum and match 
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tumor samples from the in vivo study were collected to assess the potential of miR-510 





Figure 15. Schematic of in vivo study. This study was used to test miR-510 mediated cisplatin 
sensitivity of TNBC in an in vivo setting. MDA-MB-231 SCR & 510 stables cells were 
orthotopically injected into the inguinal mammary fatpad of nude, female mice (n=24 per cell 
line). Once the tumors reached a similar size in 1 week, mice (n=12) from SCR/510 groups were 
either given an intraperitoneal injection of 100µl saline or 100µl of cisplatin (1mg/ml). 








Figure 16. In vivo study results. Tumor growth curves (A & B) and final tumor weights (C 
& D) of SCR & 510 mice from in vivo study.  
46 
 
Higher miR-510 levels were detected in serum of miR-510 overexpressing tumors. To 
explore the potential of miR-510 as a non-invasive biomarker, we assessed miR-510 in 
the serum samples from the aforementioned in vivo experiment. qPCR analysis 
indicates a statistically significant increase in serum miR-510 in 510 tumor animals 
compared to SCR tumor animals (Figure 17-B). There is a broad range of serum levels of 
miR-510 in the 510 tumor animal samples, however, tumor expression of miR-510 in the 
510 tumors displayed a broad range of expression as well (Figure 17-A).  
miR-510 expression in serum correlates with tumor expression. To further explore 
miR-510 as a non-invasive biomarker, we wanted to determine if serum expression of 
miR-510 is reflective of miR-510 expression in the tumor. As expected the miR-510 
tumors expressed significantly higher miR-510 than the SCR tumors (Figure 17-A). Since 
the serum miR-510 were higher in miR-510 tumor animals, it suggested that tumors 
overexpressing miR-510 will exhibit higher levels of it in the serum as well. To test this, 
tumor miR-510 expression were plotted against matched serum expression of miR-510. 
A Pearson’s Correlations test yielded a Pearson’s Correlation coefficient of 0.75, 
indicating a positive correlation between serum and tumor expression of miR-510 
(Figure 17-C).   
miR-510 levels detected in human breast cancer serum samples. Next, we wanted to 
determine if serum miR-510 could also be detected in human samples as well. Therefore 
we obtained breast cancer patient serum samples from MUSC Tissue Biorepository to 
assess miR-510 expression. qPCR analysis shows that various levels of miR-510 can be 
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detected in human samples as well (Figure 17-D). Serum samples of benign patients 
show a low basal expression of serum miR-510, whereas breast cancer patient serum 
samples (Grade I-III) show a higher averaged expression of serum miR-510. There does 
not seem to be a trend in serum miR-510 expression and tumor grade. These serum 
samples are from patients with various receptor subtypes of breast cancer (ER, PR, 
HER2), only two of which are triple negative breast cancer.  
Figure 17. Serum analysis of miR-510 expression. Tumor expression of miR-510 from in vivo 
experiment, assessed by qPCR (A). Samples are grouped based on tumor type (SCR vs 510) and 
treatment (saline vs cisplatin). Serum expression of miR-510 from in vivo experiment, assessed 
by qPCR (B). Samples are grouped based on tumor type (SCR vs 510). Serum miR-510 
expression vs tumor miR-510 expression of matched murine samples with a Pearson’s 
Correlation coefficient of r = 0.75 (C). Serum expression of miR-510 of human breast cancer 





 The cisplatin cytotoxicity of TNBC cell lines reveals a broad range of cisplatin 
sensitivity, representative of TNBC’s in the clinic. Of the four triple negative cell lines, 
SUM 149 cells were the most sensitive, followed by SUM159, BT549 and MDA-MB-231. 
This relative sensitivity to cisplatin between these cell lines were also observed in other 
publications [72, 73]. It should be noted that SUM149 cells harbor BRCA1 mutation and 
would possibly exhibit heightened sensitivity to cisplatin, regardless of miR-510 
expression. However, it has been shown that the proposed cisplatin-induced p73 
apoptosis pathway is active in both BRCA1-associated and sporadic TNBC (without 
BRCA1 mutations) [38]. It is well known that there is heterogeneity within the triple 
negative breast cancer subtype. Various studies have investigated elucidating subtypes 
within TNBCs. TCGA analysis has identified the basal-like molecular subtype of breast 
cancer, which significantly overlaps with TNBC [9]. Other studies have gone further, 
Neve et al. have further distinguish Basal A and Basal B subtypes [74]. Lehmann et al. 
have utilized gene expression profiling to identify six different subtypes of TNBC [73]. 
In this analysis, basal-like 1 subtype (SUM149) were the most sensitive to platinum 
chemotherapy agents. However, mesenchymal stem-like subtype (SUM159, BT549 and 
MDA-MB-231) still exhibit a broad range of sensitivity to cisplatin. This suggests that 
miRNAs may serve to further identify sensitivity in TNBC or miRNA profiling should 
be incorporated into the gene expression analysis to further breakdown TNBC into even 
more specific subtypes. Observing a tight positive correlation between miR-510 
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expression and cisplatin sensitivity in four TNBC cell lines provided encouraging 
evidence that miR-510 may serve as a potential biomarker of cisplatin sensitivity in 
TNBC. A limitation of this experiment is that SRB protocol stains for cellular protein 
content and may not a direct representation of cell viability. Assessment of cell viability 
with Trypan blue exclusion protocol will provide a more accurate representation of 
cisplatin sensitivity. Since two different assays were used to assess cisplatin sensitivity in 
the TNBC cell line screen and GOF/LOF experiments, the IC50 values for the same cell 
lines are different.  
Correlation does not imply causation and does not provide enough evidence to show 
that miR-510 directly affects cisplatin sensitivity. MDA-MB-231 cells were utilized for 
GOF studies as they express lower levels of miR-510 and are known to be intrinsically 
more resistant to cisplatin. Our GOF study demonstrates that miR-510 levels are directly 
modulating cisplatin sensitivity in TNBC cell lines, showing that elevated miR-510 
expression could sensitize resistant TNBC cells to cisplatin. While overexpression of 
miR-510 may have therapeutic potential, it is not advised since we have demonstrated 
the oncogenic potential of miR-510 in breast cancer [64]. The risk of promoting tumor 
growth and progression outweighs the benefits of sensitivity to cisplatin. The LOF study 
complements the GOF study, by showing that the loss of miR-510 is sufficient to make 
TNBC cells more resistant to cisplatin. A limitation of the LOF experiment is that BT549 
cells may be an inappropriate choice for LOF studies as its miR-510 expression is only 
slightly higher than MDA-MB-231 cells. LOF studies with additional cell lines, such as 
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SUM159 and SUM149, would provide stronger evidence that miR-510 is directly 
modulating cisplatin sensitivity. The dead cells of the Trypan blue exclusion assay in the 
GOF and LOF studies were not quantified. Although cell viability was used to assess 
cisplatin sensitivity, quantification of these dead cell may provide an understanding of 
cell death in these studies.  
GOF in MDA-MB-231 cells were validated by qPCR and showing a reduction of Prdx1 
protein. The overexpression of miR-510 in the GOF study is physiologically relevant 
compared to overexpression of miR-510 in human breast tumor samples (Figure 9). Gain 
of miR-510 expression leads to a decrease in Prdx1 protein in MDA-MB-231 as expected. 
Since the anti-miR-510 vector does not necessarily degrade miR-510, assessment of miR-
510 expression in these cells will not provide evidence of miR-510 inhibition in the LOF 
studies in BT549. However, assessment of Prdx1 protein expression in the LOF studies 
shows a restoration of Prdx1 expression, suggesting successful inhibition of miR-510 
regulation. While this data is consistent with the hypothesis that attenuated Prdx1 levels, 
through miR-510 regulation, is sensitizing tumor cells to cisplatin, these results do not 
provide direct evidence and will have to be validated in the following Prdx1 rescue 
experiments in Specific Aim 2.  
MicroRNAs are known to have many targets due to the small complementarity between 
the miRNA and mRNA that is required for regulation. While bioinformatic programs 
provide many genes that miR-510 is predicted to bind to, these targets will have to be 
experimentally validated. Due to the limited studies on miR-510, there are very few 
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validated targets for miR-510. While it is proposed here that the negative regulation of 
Prdx1, leading to TAp73 induced apoptosis, is the mechanism of miR-510 mediated 
cisplatin sensitivity, it may also be through targeting various proteins associated with 
platinum-resistance. Downregulation of various membrane transporters (e.g. MDR1, 
ATP7A, ATP7B) could lead to decreased cisplatin efflux, leading to increased sensitivity 
to cisplatin [34, 36, 37]. This could be tested by measuring the accumalation of cisplatin 
within the cell. After cisplatin binds to and damages DNA, cells could resist cell death 
by upregulating various repair pathways: nucleotide-excision repair, base-excision 
repair, mismatch repair and double-strand repair [34, 37]. This could be tested by 
assessing DNA damage within the cell upon cisplatin treatment. Inhibition of various 
signal transduction apoptotic pathways, downstream of DNA damage, could also 
render cells resistant to cisplatin [34, 36, 37]. This could be tested by various rescue 
experiments. Genes that are involved in any of these processes could also be targets of 
miR-510 regulation, providing an alternative hypothesis of the mechanism of miR-510 
mediated sensitivity to platinum agents.  
The data presented here suggests that miR-510 expression is directly modulating 
cisplatin sensitivity in TNBC and may serve as a potential biomarker of response in 
patients. MicroRNAs have emerged as candidates for novel biomarkers in cancer due to 
their involvement in various cancer processes particularly as noninvasive biomarkers, as 
they are stable in various bodily fluids and are more convenient to access than tissues 
from biopsies and surgeries [75]. Present in serum, associated with protein complexes or 
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in tumor-derived exosomes, miRNAs can be easily detected by qPCR [75-77]. Various 
studies have demonstrated the efficacy of using miRNA profiles in serum as biomarkers 
of diagnosis and prognosis in breast cancer [75] and some of these test are now available 
for clinical use (e.g. Prometheus Laboratories Inc and Rosetta Genomics) [76]. As 
expected, in mice miR-510 tumors expressed higher levels of miR-510 than SCR tumors 
and this expression was maintained throughout the course of the in vivo study. 
Interestingly, treatment of 510 tumors with cisplatin leads to upregulation of miR-510 
(Figure 17-A); this trend is also evident in the SCR tumors as well. This suggests that 
activation of downstream pathways of cisplatin treatment may promote miR-510 
expression.  
Higher levels of serum miR-510 in 510 tumor animals compared to SCR samples 
demonstrates the potential of miR-510 as a non-invasive biomarker. However there is 
still high variability within the miR-510 serum group. This could be attributed to lack of 
standardization of serum collection, processing, normalization and interpretation; 
problems that hampering the application of miRNA biomarker in the clinics [76]. 
MicroRNAs has been shown to be secreted from cells, potentially as methods of 
paracrine and endocrine signaling [53], however, serum expression of miR-510 may be 
independent of the tumor expression of miR-510. The Pearson’s Correlation Coefficient 
of 0.75 indicates a positive correlation between tumor expression and serum expression 
of miR-510. This suggests that higher levels of miR-510 in the serum is indicative of 
higher expression in the tumor, therefore more sensitive to cisplatin. Standardization of 
53 
 
the sample collection, processing and normalization, as well as more samples, is 
expected to improve the Pearson’s Correlation coefficient. Serum detection of miR-510 is 
relevant to human samples as well, since we have demonstrated that varying levels of 
miR-510 could be detected in the serum of breast cancer patients. However, the human 
serum samples are from various subtypes of breast cancer. Of the twenty samples, only 
two were TNBC, which is similar to the distribution of triple negative subtype in all 
breast cancers. It should also be noted that in control serum samples, from benign 
tumors, all exhibited low expression of miR-510. It was expected that not all but a subset 
of breast cancer patients would express miR-510 as our previous studies have shown it 
to have an oncogenic role in breast cancer. Future studies will address whether these 
patients with higher expression of miR-510 are positive responders to platinum agents in 
the clinic. There was high variability of miR-510 expression within the human samples. 
It is expected that standardization of the sample collection, processing and 
normalization may improve specificity and reproducibility. More samples are required 
to determine the expression threshold to distinguish high and low miR-510 expressing 
patients. Limitations of these studies are the limited sample size of both in vivo murine 
samples and human serum samples. Matched murine serum and tumor samples from 
the in vivo experiment were limited, particularly in SCR tumor group. Increase in 
sample size would provide a stronger evidence of correlation between tumor and serum 
expression of miR-510. Human breast cancer serum samples were also limited, 
particularly samples of TNBC. More samples would allow for us to assess if miR-510 
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expression is differentially expressed specifically in TNBC. The issues that hamper 
clinical application of miRNA markers in the clinic are also limitation of this experiment. 
Lack of standardize protocols for sample collection and preparation for miRNA analysis 
may lead to inaccurate quantification. Potential factors (i.e. fasting vs non-fasting) that 
may affect serum expression of miRNAs has yet to be explored. There is also low 
correlation between various platforms that are used to measure miRNA expression. 
Quantitation with new platforms like Digital Drop PCR (ddPCR) that provides absolute 
quantitation of miRNAs may provide more accurate assessment of miRNA expression 
than relative quantitation through qPCR. Normalization of miRNAs, particularly 
extracellular miRNAs, is also not standardized. These issues need to addressed to allow 











Specific Aim 2 
Rationale 
In specific aim 1, we have demonstrated the potential of miR-510 as a non-
invasive biomarker of cisplatin sensitivity in TNBC. However, the mechanism of how 
miR-510 mediates sensitivity is yet to be elucidated. Based on our hypothesis, miR-510 
negative regulation of Prdx1 allows for activation of TAp73 apoptotic pathway upon 
cisplatin-induced DNA damage (Figure 18). MicroRNAs are known to target many 
different genes due to the small complimentary seed site. As previously mentioned 
(specific aim 1), there are many potential mechanism of how miR-510 mediates cisplatin 
sensitivity. It is also possible that miR-510 mediated sensitivity is through multiple 
pathways. Elucidating the mechanism of this sensitivity will allow for more effective 
utilization of miR-510 as a biomarker. Understanding the mechanism could uncover 
additional markers to increase the specificity of miR-510. Understanding the pathways 
involved could help guide treatment choice by finding other drugs that may 
complement or inhibit the effectiveness of cisplatin. The goal of this aim is to 
experimentally uncover the mechanism of miR-510 mediated cisplatin sensitivity. We 
will determine if miR-510 mediated sensitivity is dependent on negative regulation of 









Figure 18. Model of miR-510 mediated cisplatin sensitivity in TNBC. miR-510 mediated negative 
regulation of Prdx1 prevents inhibition of tyrosine kinase c-Abl. Upon cisplatin treatment, c-Abl is 
activated and phosphorylates its downstream target, tumor suppressor TAp73. Once 
phosphorylated, TAp73 dissociates from its repressor ∆Np63. This allows TAp73 to transcribe pro-








Specific Aim 2: Determine if miR-510 mediated cisplatin sensitivity is through negative 
regulation of Prdx1 and the subsequent activation of the TAp73 apoptotic pathway 
 Task 1: Characterize tumor samples from in vivo study to define: 
1. If miR-510 mediated cisplatin sensitivity is through increased 
apoptosis or decreased proliferation in tumors  
2. If miR-510 negatively regulates Prdx1 in an in vivo setting 
 
Task 2: Perform in vitro mechanistic studies through RNA and protein analysis to 
define: 
1. If miR-510 mediated cisplatin sensitivity is dependent on loss of 
Prdx1 












Tissue sectioning: MDA-MB-231 SCR and 510 tumors, treated with saline or cisplatin, 
from the aforementioned study (Figure 15), were stored in 70% ethanol at 4°C. The 
tumors were dehydrated by passing through 95% ethanol twice and then 100% ethanol 
twice, for 1 hour each. Tumor samples were then placed into 100% toluene twice for 4 
hours each. Next the sample was placed in 50:50 mixture of toluene/paraffin overnight at 
60°C. The 50:50 mixture of toluene/paraffin was removed and 100% paraffin is added to 
the samples, twice for 2 hours each, at 60°C. The samples were embedded in cassettes 
with the EG1160 paraffin embedding station (Leica, Buffalo Grove, IL).  The tumors are 
then sectioned (5 microns thickness) with Jung RM2055 microtome (Leica, Buffalo 
Grove, IL) and mounted onto Superfrost Plus glass slides (Fisher, Hampton, NH) for 
immunohistochemistry (IHC).  
Immunohistochemistry: For IHC, slides were incubated in a 60°C oven for 1 hour and 
then placed in xylene (Fisher, Hampton, NH) for 10 minutes and then rehydrated with 
serial incubations in decreasing ethanol concentrations (100%, 95%, 70% and 50%) for 10 
minutes each. Next, the slides were subjected to heat-induced antigen retrieval by 
heating slides in a vegetable steamer with 1% citrate buffer solution (Vector Labs, 
Burlingame, CA) for 30 minutes. Slides were further washed with 1X PBS twice for 3 
minutes each and then incubated with 0.3% hydrogen peroxide (Fisher, Hampton, NH) 
to sequester endogenous peroxidase activity for 30 minutes. The slides were then 
washed with 1x PBS-Tween (0.05%) for 5 minutes before blocking with 2.5% horse 
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serum (Vector Labs, Burlingame, CA) at 25°C in an incubation chamber.  Next, the slides 
were incubated with the following primary antibodies, diluted in 2.5% horse serum, 
overnight at 4°C: Ki-67 1:200 dilution (Santa Cruz, Dallas, TX), cleaved caspase 3 1:500 
dilution (Cell Signaling, Danvers, MA) and Prdx1 1:1000 dilution (Abcam, Cambridge, 
MA). After overnight incubation in primary antibody, the slides were washed 3 times 
for 5 minutes each with 1X PBS and then incubated with peroxidase conjugated, anti-
rabbit secondary antibody (Vector Labs, Burlingame, CA) for 30 minutes. The slides 
were washed again, 3 times for 5 minutes each with 1X PBS, stained with 
Diaminobenzidine (DAB) (Sigma, St. Louis, MO) for 30 seconds and then counterstained 
with hematoxylin (Fisher, Hampton, NH) for 2 minutes. Slides were then dehydrated 
with serial incubation in increasing concentrations of ethanol (50%, 70%, 95% and 100%) 
and xylene for 5 minutes each. Finally, slides were mounted with Permount ® (Fisher, 
Hampton, NH) and a glass coverslip (Fisher, Hampton, NH). Images of the slides were 
taken with a Nikon Eclipse 90i microscope (Nikon, Melville, NY) at 40x magnification; 
images of 5 random, non-overlapping fields of view were taken for each tumor. For 
proliferation quantitation, Ki-67 positive cells were counted and plotted as a percentage 
of the total number of cells in each field using ImageJ software (NIH, Bethesda, MD). 
The counts from 5 fields of view were then averaged and presented together with 
tumors of the same experimental group. The cleaved caspase 3 slides were quantified in 
a similar fashion, averaging total number of positively stained cells in 5 fields of view 
using ImageJ software (NIH, Bethesda, MD) and then averaged between all tumors of 
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the same experimental group. For Prdx1 quantitation, images were scored based on 
intensity of staining (0 for no staining, 1 for low staining, 2 for moderate staining, 3 for 
high staining, and 4 for very high staining). These scores were averaged and were 
plotted against miR-510 expression (from specific aim 1) from matched tumor. These 
quantitations were performed by two people and then averaged to minimize observer 
bias.  
Prdx1 rescue experiment: MDA-MB-231 SCR & miR-510 stable cells were plated at a 
density of 1.5x105 cells/well in two 6 well plates. After 24 hours, cells were transiently 
transfected either with the Prdx1 ORF vector (without 3’UTR) or an empty vector 
control using the XTREME Gene HP reagent protocol as previously described above 
(specific aim 1) (Roche, Nutley, NJ). After 24 hours, cells were treated with cisplatin (0, 3 
and 10M).  After 24 hours, cell viability was assessed using Trypan blue exclusion 
assay as previously described. Cell pellets were collected to assess Prdx1 protein 
expression by western blot as described above (specific aim 1) using Prdx1 antibody 
(1:1000 dilution; Abcam, Cambridge, MA).  
Assessment of TP73, PUMA, and NOXA mRNA: MDA-MB-231 SCR & 510 stable cells 
were plated at a density of 2.0x105 cells/well in a 6 well plate and cultured as previously 
described. After 24 hours, the cells for TP73 mRNA assessment were treated with 0M 
and 10M cisplatin for 0, 6, 12, and 24 hours. Cells for PUMA and NOXA mRNA 
assessment were treated with 0M and 3M cisplatin for 0, 6, 12, and 24 hours.  Cells 
were then collected for RNA analysis.   
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RNA extraction and quantitative Real-Time PCR analysis: Cells were collected and 
processed for RNA extraction as previously described (specific aim 1). RNA was then 
reverse transcribed into cDNA and TAp73, PUMA, NOXA and GAPDH transcript 
expression was quantified using qPCR as previously described. Primer sequences and 
UPL probe number for each gene are listed in Table 1. All samples were run in 
triplicates. The relative expression of each gene was quantified on the basis of Ct values 
in comparison to an internal standard curve for each gene using the software provided 
by the manufacturer (Roche, Nutley, NJ). All mRNA expression was normalized to 
GAPDH.  
Immunoprecipitation and Western Blot analysis: MDA-MB-231 SCR & miR-510 stable 
cells were plated at a density of 1.0x106 cells/10cm plate. Once the cells reached ≤ 90% 
confluency, cells were treated with 0 and 10µM cisplatin for 6 hours. After 6 hours, cell 
media was removed from the plates and washed with cold 1X PBS. Next, 500µl of RIPA 
buffer (specific aim 1), with Na3VO4 and NaF phosphatase inhibitors, were added to 
each plate and cell lysates were collected by scraping. Protein extraction was performed 
as previous described (specific aim 1). For the phospho-p73 experiment, cell lysates were 
subjected to immunoprecipitation with p73 antibody. Magnetic NovexTM DynabeadsTM 
Protein G beads (100µl) are incubated with 2 µg of p73 (s-20) antibody (Santa Cruz, 
Dallas, TX) for 1 hour. The magnetic bead/p73 conjugate is washed and resuspended in 
100µl of 2% BSA/PBS solution. For immunoprecipitation, 500µg of protein lysate was 
incubated with 50µl of the magnetic bead/p73 antibody conjugate overnight at 4°C with 
62 
 
agitation. After incubation, beads were washed 3 times by resuspending in cell lysis 
buffer, isolate complex with a magnet and aspirating the supernatant. Beads were 
resuspended in 25µl of 2x Laemmli Buffer (Bio-RAD, Hercules, CA) and boiled for 10 
minutes. Magnetic beads were captured with a magnet and the supernatant was used 
for Western Blot analysis as previously described (specific aim 1) using phospho-p73 
antibody 1:1000 (Cell Signaling, Danvers, MA). An input blot of 50µg of total lysate was 
also performed using p73 (s-20) antibody (1:200; Santa Cruz, Dallas, TX) and GAPDH 
(1:1000; Santa Cruz, Dallas, TX), with anti-goat (1:1000; Santa Cruz, Dallas, TX) and anti-
rabbit (1:2000; GE Healthcare, Piscataway, NJ) secondary antibodies, respectively. For 
the ∆Np63/p73 dissociation experiment, cell lysates were subjected to 
immunoprecipitation with p63 antibody. Magnetic NovexTM DynabeadsTM Protein G 
beads (100µl) are incubated with 2 µg of p63 antibody (Cell Signaling, Danvers, MA) for 
1 hour. The magnetic bead/p63 antibody conjugate is washed and resuspended in 100µl 
of 2% BSA/PBS solution. For immunoprecipitation, 500µg of protein lysate was 
incubated with 50µl of the magnetic bead/p63 antibody conjugate overnight at 4°C with 
agitation. After incubation, beads were washed with 3 times by resuspending in cell 
lysis buffer, isolate complex with a magnet and aspirating the supernatant. Beads were 
resuspended in 25µl of 2x Laemmli Buffer (Bio-RAD, Hercules, CA) and boiled for 10 
minutes. Magnetic beads were captured with a magnet and the supernatant was used 
for Western Blot analysis as previously described (specific aim 1) using p73 (s-20) 
antibody (1:200; Santa Cruz, Dallas, TX). An input blot of 50µg of total lysate was also 
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performed using p63 antibody (1:1000; Cell Signaling, Danvers, MA) and GAPDH 
(1:1000; Santa Cruz, Dallas, TX), both with anti-rabbit (1:2000; GE Healthcare, 


















miR-510 mediated cisplatin sensitivity is not through decreased proliferation in vivo. 
Immunohistochemistry analysis of tumors from the in vivo study was performed to 
provide insights on the mechanism of miR-510 mediated tumor size reduction upon 
cisplatin treatment. To investigate whether this reduction in tumor volume is due to 
decrease in proliferation, Ki-67 IHC quantitation was performed. Ki-67 IHC of the tumor 
sections indicate similar percentage of proliferating cells between saline and cisplatin 
treated animals in both SCR and 510 tumors. There is a statistically significant difference 
of proliferation rates between the Scr and miR-510 saline treated groups (Figure 19); this 
is consistent with our previous publication, showing that miR-510 increases tumor cell 
proliferation. Similar proliferation trends between the saline and cisplatin treated 
groups, suggests that the role of miR-510 mediated cisplatin sensitivity may not be 
through inhibition of tumor cell proliferation. 
miR-510 mediated cisplatin sensitivity is not through increased cleaved-caspase 3 
dependent apoptosis in vivo. Next, we wanted to investigate whether miR-510 
mediated reduction in tumor volume is attributed to increased apoptosis. Cleaved 
caspase 3 IHC of the tumor sections showed a non-significant difference in apoptosis 
between saline and cisplatin treatment in the SCR group. Quantification of 
saline/cisplatin treated 510 tumors also did not reach statistical significance (Figure 20). 
These data suggest that the mechanism of miR-510 mediated cisplatin sensitivity is not 









Figure 19.  Proliferation profile of in vivo study murine tumors. Representative images of 
hematoxylin and eosin staining and Ki67 IHC staining of murine tumors (A). Quantitation of 
proliferation in tumors with samples grouped together based on tumor (SCR vs 510) and treatment 



















Figure 20. Cleaved-caspase 3 apoptosis profile of in vivo study murine tumors. Representative 
images of hematoxylin and eosin staining and cleaved-caspase 3 IHC staining of murine tumors 
(A). Quantitation of cleaved-caspase 3 dependent apoptosis in tumors with samples grouped 





miR-510 negatively regulates Prdx1 expression in vivo. Assessing Prdx1 protein levels 
in tumor samples from the in vivo study provided evidence that miR-510 is negatively 
regulating Prdx1 in an in vivo setting. Quantitation of tumor Prdx1 protein expression 
with representative tumors from each experimental group is shown (Figure 21). Tumors 
were grouped together based on Prdx1 IHC score and plotted against matched tumor 
expression of miR-510 (specific aim 1). There is no statistical significant difference of 
miR-510 expression between Prdx1 IHC 1 and 2 score tumors. Tumors with Prdx1 IHC 
score of 3 and 4 shows a significant decrease in miR-510 expression compared to Prdx1 
IHC score 2 tumors. A negative correlation between miR-510 expression and Prdx1 
expression in the tumors indicates miR-510 is negatively regulating Prdx1 expression in 
vivo, consistent with our previous in vitro experiments. This also suggests that 
downregualtion of Prdx1 in miR-510 tumors may be a potential mechanism of miR-510 











         
Figure 21. Prdx1 expression of in vivo study murine tumors. Quantitation of Prdx1 IHC in 
murine tumors from the in vivo experiment with samples grouped together based on Prdx1 IHC 
score. Samples are plotted against miR-510 expression of matched tumor samples. 




miR-510 mediated cisplatin sensitivity is dependent on negative regulation of Prdx1. 
In order to determine whether the mechanism of miR-510 mediated sensitivity is 
through our proposed pathway (Figure 18), we first wanted to determine whether miR-
510 mediated sensitivity is directly through Prdx1 downregulation by performing a 
Prdx1 rescue experiment (Figure 22-A). MDA-MB-231 SCR & 510 stable cells were 
transfected with an empty vector (ev) or Prdx1 rescue vector (Prdx1’). The Prdx1’ 
plasmid encodes Prdx1 transcript without its 3’ UTR, the regulatory region of which 
miRNAs bind, and allows for the translation of Prdx1 even in the presence of miR-510. 
To determine whether Prdx1 rescue was successful, a Western blot was performed 
(Figure 22-B). The Western blot shows a significant reduction in Prdx1 expression in 510-
ev cells compared to SCR-ev cells as expected. Both SCR-Prdx1’ and 510-Prdx1’ cells 
show upregulation of Prdx1 protein expression compared to their ev cells. The 510-
Prdx1’ cells expression of Prdx1 is close to levels in SCR-ev cells, showing that the 
Prdx1’ vector has successfully rescued Prdx1 expression in the 510 cells. Next, these cells 
were treated with increasing concentration of cisplatin and viability was assessed 
(Figure 22-C) to determine whether miR-510 mediated sensitivity is dependent upon 
Prdx1 expression. There is no difference in cisplatin sensitivity between SCR ev and 
Prdx1’ cells. Consistent with Figure 13, there is a significant decrease in viability of the 
510-ev cells compared to SCR-ev cells, indicating a higher cisplatin sensitivity with miR-
510 overexpression. Treating the 510-Prdx1’ cells with cisplatin revealed a similar 
cisplatin sensitivity as the SCR cells. This shows that rescue of Prdx1 protein expression 
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in miR-510 overexpressing cells ablates miR-510 mediated cisplatin sensitivity, making 
them as sensitive as the SCR cells. This suggests that the mechanism of miR-510 
mediated cisplatin sensitivity is, at least in part, dependent upon its negative regulation 





Figure 22. Prdx1 rescue experiment. Prdx1 rescue experiment will determine if miR-510 mediated 
cisplatin sensitivity is through its negative regulation of Prdx1, highlighted in pathway model (A). 
Western blot analysis of Prdx1 expression in MDA-MB-231 SCR/510 cells transfected with an 
empty vector (ev) control or Prdx1’ rescue vector (B). Viability of in MDA-MB-231 SCR/510 cells 
transfected with an empty vector (ev) control or Prdx1’ rescue vector, treated with increasing 




Overexpression of miR-510 leads to upregulation and increased phosphorylation of 
TAp73 upon cisplatin treatment. Next, we wanted to determine if miR-510 
overexpression leads to the phosphorylation of TAp73 upon cisplatin treatment (Figure 
23-A) . MDA-MB-231 SCR & 510 stable cells, treated with 0 and 10µM cisplatin for 6 
hours, were subjected to immunoprecipitation with p-73 antibody conjugated magnetic 
beads. Western Blot analysis with phospho-p73 antibody (Figure 23-B) reveals induction 
of phospho-p73 only in the 510 cells treated with cisplatin. This suggests that under 
these conditions the TAp73 pathway is activated only in miR-510 cells treated with 
cisplatin. We also wanted to assess the expression of total TAp73 by analyzing the input 
lysate by Western blotting (Figure 23-B). There is significant upregulation of total TAp73 
protein in 510 cells treated with cisplatin, whereas this upregulation was not seen in the 
SCR cells. To further investigate the mechanism of TAp73 protein upregulation, qPCR 
analysis was performed to quantify TP73 mRNA expression at various time points after 
cisplatin treatment (Figure 23-C). This analysis shows similar levels of TP73 transcripts 
in the SCR and 510 cells at the 6 hrs time point, when the protein expression of TAp73 
was assessed. Treatment for 24 hrs leads to statistically significant increase in TP73 
mRNA in both SCR and 510 cells. However, a significantly higher induction of TP73 
mRNA is observed in 510 cells compared to SCR cells (2.5 fold increase vs 1.5 fold 












Figure 23. TAp73 phosphorylation. This experiment will provide evidence that miR-510 
overexpression leads to activation of the TAp73 pro-apoptotic pathway upon cisplatin treatment 
through promoting TAp73 phosphorylation, highlighted in the pathway model (A). Western blot 
analysis of p-p73 from p73 IP lysates, along with total p73 and GAPDH protein expression in 
MDA-MB-231 SCR/510 cells treated with 10 µM cisplatin for 6 hrs (B). Expression of TP73 mRNA, 
assessed by qPCR, of MDA-MB-231 SCR/510 cells treated with 10 µM cisplatin for 0, 6, 12, and 24 




Overexpression of miR-510 leads to dissociation of TAp73 and ∆Np63 upon cisplatin 
treatment. In the proposed mechanistic pathway, phosphorylation of TAp73 leads to the 
dissociation of its repressor ∆Np63 (Figure 24-A). To investigate this dissociation of 
∆Np63 / TAp73, cell lysates from the TAp73 phosphorylation study were subjected to 
immunoprecipitation with p63 antibody and then analyzed by Western blot with a p73 
antibody (Figure 24-B). There was less TAp73 protein associated with ∆Np63 
immunoprecipitation in the 510 cells treated with cisplatin compared to untreated cells. 
There was no reduction of TAp73 association with ∆Np63 in SCR cells treated with 
cisplatin. Western blot analysis of whole cell lysate reveals similar expression of total 
p63 in all the samples. This data provides additional evidence that overexpression of 















Figure 24. Dissociation of ∆Np63/TAp73. This experiment will provide evidence that miR-510 
overexpression leads to activation of the TAp73 pro-apoptotic pathway upon cisplatin treatment 
through promoting dissociation of ∆Np63/TAp73, highlighted in the pathway model (A). Western blot 
analysis of p73 from p63 IP lysates, along with p63 and GAPDH protein expression in MDA-MB-231 








miR-510 overexpression leads to induction of p73 target genes in response to cisplatin 
treatment. To further uncover evidence of TAp73 activation, we assessed PUMA and 
NOXA mRNA expression, downstream target genes of TAp73 (Figure 25-A). PUMA and 
NOXA transcript levels were assessed by qPCR in MDA- MB-231 SCR & 510 cells 
treated with 3µM cisplatin for 0, 6, 12, and 24 hrs. A statistically significant increase in 
PUMA mRNA (Figure 25-B) was observed in miR-510 overexpressing cells after 6, 12, 
and 24 hrs of cisplatin treatment. A significant increase of NOXA mRNA (Figure 25-C) 
was observed in miR-510 overexpressing cells after 24 hrs of cisplatin treatment. This 
provides evidence that TAp73 transcriptional activity and the p73-dependent apoptotic 















Figure 25. Induction of pro-apoptotic TAp73 genes. This experiment will provide evidence that 
miR-510 overexpression leads to activation of the TAp73 pro-apoptotic pathway upon cisplatin 
treatment through induction of pro-apoptotic, TAp73 target genes, highlighted in the pathway 
model (A). Expression of PUMA (B) and NOXA (C) mRNA, assessed by qPCR, of MDA-MB-231 





 The data from the previous aim has demonstrated that miR-510 expression 
could directly modulate cisplatin sensitivity. Next, the mechanism of miR-510 mediated 
cisplatin sensitivity was explored to determine if it is through the proposed p73 
apoptotic pathway. This will allow for more specific identification of sensitive patients 
by assessing additional markers (i.e. p53 mutations, c-Abl mutations, ratio of 
∆Np63/TAp73) as well as identify agents that may reduce efficacy of this pathway (i.e. 
kinases inhibitors). To gain insight on the mechanism of miR-510 mediated cisplatin 
sensitivity, tumors from the in vivo study were analyzed. Reduction of tumor size could 
be attributed to decreased proliferation of the tumor, increased cell death (apoptosis or 
necrosis) or a combination of both. While the main mechanism of cisplatin is inducing 
apoptosis, cisplatin could also induce cell cycle arrest (S phase and G2 phase) [36]. Ki-67 
is used as a marker for the assessment of proliferation, a non-histone nuclear protein 
that is closely linked with cell cycle and proliferation, emerging as a prognostic marker 
in various cancers, including breast cancer [78]. A significant increase in proliferation in 
the 510 overexpressing tumors compared to SCR tumors is consistent with our previous 
publication, that miR-510 promotes proliferation in breast cancer [64]. The similar 
proliferation profiles between saline and cisplatin treated 510 tumors suggests that cell 
cycle arrest and inhibition of proliferation may not be the main mechanism of miR-
510/cisplatin induced reduction of tumor volume in the in vivo study.  
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The tumors were then quantified for apoptosis, to provide evidence to determine if miR-
510/cisplatin mediated reduction of tumor volume is attributed to increased apoptosis. 
Cisplatin has been shown to induce both necrosis and apoptosis as main modes of cell 
death [36]. The mode of cell death is dependent upon the concentration of cisplatin. One 
study showed that treatment of mouse proximal tubular cells with a high concentration 
of cisplatin (800µM) leads to necrotic cell death, whereas, treatment with low 
concentration of cisplatin (8µM) leads to apoptotic cell death [79]. Since the 
concentrations of cisplatin used in the in vitro studies are similar to the low 
concentration used in the aforementioned study, it is believed that apoptosis may be the 
main mechanism of cisplatin induced cell death in miR-510 overexpressing cells. 
Cisplatin insult has been shown to promote activation of the caspase family of proteases 
that ultimately commits the cell to undergo irreversible apoptotic cell death [36, 80]. 
Activation of initiator caspases (caspase 8 and caspase 9) leads to cleavage and 
activation of effector caspases (caspase 3 and caspase 7). Activated effector caspases then 
begin proteolytic cleavage of various cellular proteins leading to apoptosis of the cell [36, 
81]. The lack of statistically significant difference of cleaved- caspase 3 in treated and 
untreated 510 tumors suggests that miR-510 mediated sensitivity may not be through 
cleaved-caspase 3 pathway of apoptosis. Since cleavage of caspase 3 is a transient 
process, our experimental design and low sample numbers may limit the ability to 
detect the differences in cleaved caspase 3 by IHC. Another possible explanation is that 
caspase-dependent apoptosis is not the main mechanism of miR-510 mediated cell death 
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in these tumors upon cisplatin treatment. Various studies have demonstrated caspase-
independent pathways of apoptosis upon cisplatin treatment [82, 83]. Lack of 
statistically significant differences in cleaved-caspase 3 between saline/cisplatin treated 
tumors and the relatively low expression of cleaved-caspase 3 in all tumor groups 
suggests that cisplatin induced apoptosis in these tumors are not caspase dependent. 
Another possible explanation is that cisplatin is known to interact with various 
molecules in the cell besides DNA, including molecules that are involved in maintaining 
cellular metabolism and energy supply. This could lead to situations, such as ATP 
depletion that lead to cell death prior to completion of apoptotic pathway signaling. This 
leads to cisplatin-induced cell death that lacks characteristic morphological and 
biochemical properties of “classic” apoptosis [37, 80]. A better understanding of 
apoptosis within these tumors could be assessed by employing additional IHC markers 
of apoptosis: cleaved cytokeratin-18, cleaved lamin A, cleaved poly (ADP ribose) 
polymerase (PARP) and translocation of apoptosis-inducing factor (AIF) [81]. An 
alternative method of apoptosis detection in tissue samples, like the terminal 
deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) assay [84], 
could also be employed. Limitation of these IHC analysis is the small sample size of 
murine tumors from the in vivo study. A larger sample size would provide a better 
representation of proliferation and apoptosis within these tumors.  
In our previous publication, Prdx1 was experimentally validated as a direct target of 
miR-510 [64].  However, this direct negative regulation has not been verified in an in 
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vivo setting. We demonstrated here that miR-510 negatively regulates Prdx1 in an in vivo 
setting and could be a possible mechanism of cisplatin induced reduction in volume of 
miR-510 tumors. However, the negative correlation between miR-510 and Prdx1 does 
not provide direct evidence that downregulation of Prdx1 is directly leading to cisplatin 
sensitivity. 
Quantitation of in vivo tumors indicate miR-510 mediated sensitivity is most likely 
through downregulation of Prdx1 and subsequently inducing apoptosis upon cisplatin 
treatment. In the proposed pathway, cisplatin-induced DNA damage leads to c-Abl 
activation and phosphorylates downstream target, TAp73. Upon phosphorylation of 
TAp73, it dissociates from its repressor ∆Np63. This allows TAp73 to become 
transcriptionally active, transcribing genes to promote cell cycle arrest and apoptosis. 
We hypothesize that expression of miR-510 allows for upregulation of this pro-apoptotic 
pathway upon cisplatin treatment in TNBC. As miRNAs are known to target many 
genes simultaneously, miR-510 mediated sensitivity may be through negative regulation 
of other genes besides Prdx1 or even a combination of genes. As previously mentioned 
in specific aim 1, miR-510 mediated sensitivity maybe through negative regulation of 
genes involved in cisplatin resistance. Negative regulation of membrane transporters 
involved in efflux of cisplatin, DNA damage recognition and repair proteins, proteins of 
pro-survival pathways and inhibitor proteins of pro-apoptotic pathways could all 
potentially lead to cisplatin sensitivity. A bioinformatics screen could be used to identify 
candidate target genes of miR-510 that are involved in these processes. To determine 
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whether miR-510 targets these proteins, it would require experimental validation 
through luciferase assay or RNA binding protein immunoprecipitation microarray (RIP-
Chip). Restoration of cisplatin resistant in miR-510 overexpressing cells by rescuing 
Prdx1 expression provides evidence that miR-510 mediated cisplatin sensitivity is 
dependent upon downregulation of Prdx1. However, cisplatin is known to activate 
many downstream pathways and miR-510 could potentially target many proteins of 
these pathways. It is unlikely that negative regulation of Prdx1 is the only mechanism of 
miR-510 mediated sensitivity, but it may be the main mechanism. This will have to be 
explored through identifying novel targets of miR-510 and rescue experiments.  
After demonstrating that Prdx1 plays a role in miR-510 mediated cisplatin sensitivity, 
we further explore the mechanism of cell death by examining pathways downstream of 
Prdx1. It is proposed that downregulation of Prdx1 prevents its inhibition of c-Abl, 
allowing for increased phosphorylation of c-Abl targets, TAp73. Besides c-Abl, Prdx1 
has been shown to play a role in other pathways that may contribute to increased 
resistance to cisplatin. The main function of Prdx1, as an antioxidant enzyme, is to 
protect cells from oxidative damage by reducing cellular ROS, RNS, and thiyl radicals 
[65]. Through its antioxidant activities, Prdx1 has been shown to protect cells from 
ionizing and ultraviolet radiation induced cell death [67, 68]. Like many other 
chemotherapy drugs, cisplatin is pro-oxidant and known to lead to ROS accumulation 
and subsequent cell death [85, 86]. However, studies of cisplatin resistance through 
reduction of cisplatin-induced ROS formation is mainly attributed to glutathione, 
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another family of thiol-peroxidases [85, 86]. This implies that the role of Prdx1 in 
cisplatin sensitivity is not through reduction of its peroxidase activity. The catalytic 
activity of Prdx1 is dependent upon two cysteine residues, which could be mutated to 
serine to inhibit its peroxidase activity [87]. This will help determine whether the role of 
Prdx1 is independent of its peroxidase activity. Previous studies have demonstrated 
that, aside from its enzymatic activities, Prdx1 has been shown to be interact with 
various proteins involved in regulation of cell signaling, proliferation and apoptosis [65, 
66]. Prdx1 has been shown to inhibit proteins such as ASK1, JNK, p38, ERK, p66Shc and c-
Abl [65, 69], many of which are also involved in downstream signaling of cisplatin-
induced DNA damage [36, 37]. Prdx1 has also been shown to act as a chaperone protein 
by binding to transcription factors (NF-ĸB and c-Myc) and modulate gene expression in 
the nucleus [65]. While all these interactions of Prdx1 could contribute to its role in 
cisplatin sensitivity, we focus on the interaction between Prdx1 and c-Abl. In the 
proposed pathway, cisplatin-induced DNA damage activates c-Abl to transmit DNA 
damage signals from the nucleus to the cytoplasm. Downregulation of Prdx1 prevents 
inhibition of c-Abl kinase activity allowing it to phosphorylate its downstream effector, 
TAp73. Studies have shown phosphorylation of tyrosine residue on TAp73 is required 
for it dissociation from Np63 and its activation [38]. Immunoprecipitation with p73 
antibody and subsequent Western blotting with phospho-p73 antibody reveals that 
there is an increase in p73 phosphorylation only in miR-510 overexpression cells treated 
with cisplatin. This suggests that there is an increase c-Abl kinase activity with miR-510 
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overexpression upon cisplatin treatment. The phospho-p73 antibody used lacks 
specificity, as it has been shown to cross-react with phospho-p63 due to high homology 
between the two proteins. Therefore, immunoprecipitation with a p73 antibody was 
employed to enrich p73 and help improve specific detection of phospho-p73 within our 
samples. Various proteins have been shown to phosphorylate p73 besides c-Abl, 
including PKCδ, Chk1 and JNK [88, 89]. However, these are all serine/threonine kinases 
that only phosphorylate serine/threonine residues on p73. The phospho-p73 antibody 
used recognizes phospho-tyrosine residue and since c-Abl is the only tyrosine kinase 
known to phosphorylate p73, this suggests that c-Abl kinase activity is enhanced during 
miR-510 overexpression upon cisplatin treatment. Based on our model and previous 
publications, phosphorylation of the tyrosine residue on TAp73 allows it to dissociate 
from its repressor ∆Np63 [27, 38]. This dissociation is crucial for TAp73 activation and 
transcription of downstream targets PUMA and NOXA and subsequent sensitivity to 
cisplatin. Evidence from the p63 immunoprecipitation study suggests that miR-510 
overexpression allows for increased dissociation of TAp73 from ∆Np63 upon cisplatin 
treatment.   
It has been previously shown that cisplatin induced activation of c-Abl leads to 
increased TAp73 protein levels, most likely through increasing the half-life of the 
protein [90]. Other studies has demonstrated that phosphorylation of TAp73 by c-Abl is 
required for the stabilization of the protein, thus increasing its accumulation in cells after 
cisplatin treatment [89, 91]. Since we have shown a higher level of phosphorylated 
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TAp73 and total TAp73 in the 510 cells upon cisplatin treatment, it suggests that increase 
in TAp73 accumulation is attributed to p73 protein phosphorylation and stabilization. 
Although increase in total TAp73 could allow for higher phosphorylation as well, 
previous studies showing that phosphorylation of tyrosine-99 leading to stabilization 
suggests that phosphorylation occurs prior to accumulation, not vice versa. The tyrosine 
residue could be mutated to an alanine to further determine if stabilization and 
accumulation of TAp73 is dependent on its phosphorylation. Acetylation of TAp73 by 
acetyltransferase p300 has also been shown as an alternative mechanism of p73 
stabilization [89]. Increase in total TAp73 protein expression could also be attributed to 
various mechanism besides protein stabilization, including: increased transcription, 
mRNA stabilization, and increased translation. Since TP73 mRNA does not increase in 
510 cells treated with cisplatin for 6 hrs (Figure 23-C), it suggests that the mechanism of 
TAp73 protein expression upregulation may be through protein stabilization. The 
increase in protein expression could also be explained by increase translation of TAp73 
mRNA in the 510 overexpressing cells. This could be further tested with assays such as 
polysome profiling or pulsed SILAC. Treatment of cisplatin for 24 hours leads to 
significant increase in TP73 mRNA in both the 510 and SCR cells (Figure 23-C), although 
it is significantly higher in the 510 cells (2.5 fold vs 1.5). This upregulation of TP73 
mRNA could be through a parallel pathway or downstream of the TAp73 pro-apoptotic 
pathway. To rule out the possibility that TAp73 upregulation is due to mRNA 
upregulation, the cells could be treated with a transcription inhibitor to see whether 
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TAp73 protein expression is dependent on increased transcription. The increase in 
TAp73 protein levels may indicate increase protein activity, but will have to be further 
investigated. While kinase activity of c-Abl is required for the cisplatin-induced cell 
death by p73, phosphorylation of tyrosine residue (Tyr-99) has mainly been shown to 
increase stabilization of p73 protein [89-91]. Phosphorylation of Ser-289 and Ser-47 on 
p73 by PKCδ and Chk1, respectively, has been shown to modulate the transcriptional 
and pro-apoptotic activity of p73 [89]. This suggests that overexpression of miR-510 
allows for the increase kinase activity of c-Abl, upon cisplatin treatment, by 
phosphorylating p73 to stabilize its expression and therefore allowing increased 
phosphorylation of its serine residues to upregulate its downstream, pro-apoptotic 
functions.     
PUMA and NOXA are downstream apoptotic effectors of the c-Abl:TAp73 pathway and 
are transcriptionally regulated by TAp73 in response to cisplatin. Upon their 
transcriptional upregulation, PUMA and NOXA promote mitochondrial translocation of 
pro-apoptic BAX and mitochondrial dysfunction, leading to release of apoptogenic 
proteins and cell death [92]. While upregulation of mRNA is not directly indicative of 
increase transcription of these genes, previous data has shown increase TAp73 
phosphorylation, dissociation of the TAp73-repressor ∆Np63 and accumulation of total 
TAp73 suggests that the increase of PUMA and NOXA mRNA, in miR-510 
overexpressing cells, is most likely attributed to increased transcriptional activity of 
TAp73 upon cisplatin treatment. To distinguish this mechanism from stabilization of 
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PUMA and NOXA mRNA, further studies with nuclear run on assays are required. 
However, PUMA and NOXA transcription could also be attributed to other 
transcription factors besides TAp73. Due to the high homology between p53 family 
members (TAp53, TAp63 and TAp73) they are predicted to target transcription of many 
similar genes, including PUMA and NOXA [38, 93]. Since MDA-MB-231 has a pro-
survival form of mutant p53 [94], PUMA and NOXA are unlikely transcribed by p53 in 
these cell lines. Although TAp63 may or may not play a role, further evidence is needed 
to rule out role of TAp63 in PUMA and NOXA induction. Knockout of TAp73 in these 
cells will determine if PUMA and NOXA are being transcribed by TAp73. Once again, 
the previous data showing increased p73 phosphorylation, dissociation of the TAp73-
repressor ∆Np63 and accumalation of total TAp73 indicate that PUMA and NOXA 
transcription is attributed to increased transcriptional activity of TAp73 upon cisplatin 
treatment. 
The cumulative data supports the hypothesis that elevated miR-510 levels leads to 
upregulation of the proposed TAp73 apoptotic pathway. These experiments have 
demonstrated that miR-510 mediated negative regulation of Prdx1 is required for 
cisplatin sensitivity, leading to increased phosphorylation of p73, dissociation of ∆Np63 
from p73, p73 protein accumulation and increased expression of pro-apoptotic genes 
PUMA and NOXA upon cisplatin treatment. However further experiments will have to 
be completed to fully characterize the mechanism of miR-510 mediated, cisplatin 
induced cell death, including c-Abl knockdown experiments (imatinib or c-Abl shRNA) 
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and p73 knockdown experiments (p73 shRNA). Despite this evidence, it is unlikely that 
it is the only mechanism of miR-510 mediated cisplatin sensitivity. The Prdx1 rescue 
experiment indicate that miR-510 mediated cisplatin sensitivity is mainly through 
negative regulation of Prdx1. Cisplatin induced DNA damage is known to activate 
various pathways besides c-Abl, including MAPK pathways (p38, JNK and ERK). Prdx1 
is also known to play a regulatory role in these pathways, suggesting a parallel 
apoptotic signaling pathway that could be independent of, or acting synergistically with, 
c-Abl signaling. It should also be noted that TAp73 could be subjected to various post-
translational modifications that affects its function. Most notable of these modifications 
is phosphorylation of p73 by various kinases, including c-Abl, PKCδ, Chk1 and JNK [88, 
89]. Phosphorylation of each residue by different kinases play a different role in p73-
mediated apoptosis. Further exploration of these other pathways will help uncover the 
complex mechanism of miR-510 mediated cisplatin sensitivity in TNBC. The limitation 
of these mechanistic studies is that they were performed in only one TNBC cell line. 
While we provide evidence of TAp73 pro-apoptotic pathway activation upon 
overexpression of miR-510 in MDA-MB-231 cells, this pathway may be specific to MDA-
MB-231 cells. Further mechanistic studies are required in other TNBC cell lines to 






Breast cancer is recognized not as single entity but as a heterogeneous group of 
diseases. As conventional methods are still employed to categorize and treat these 
diseases, it is becoming more evident that there is still high heterogeneity within these 
subtypes. Although the emphasis on early detection and advances in treatment has 
improved breast cancer survival, the triple negative subtype of breast cancer is still 
associated with the poorest prognosis of all breast cancer subtypes. TNBC is less likely 
to be detected early through mammograms, when a cure is more likely and tumors are 
most responsive to treatment. Due to lack of receptors, effective targeted therapies are 
not available for TNBC and cytotoxic chemotherapy remains the standard of care. 
Therefore, there is currently extensive research on development of targeted therapies for 
TNBC. This would help prevent progression into late stage disease where TNBC has the 
poorest survival rates compared to all other subtypes of breast cancer.  
Platinum agents, such as cisplatin, have emerged as a novel therapy to treat 
TNBC, due to its aberrant DNA repair mechanisms. However, the heterogeneity of 
TNBC was once again demonstrated as cisplatin was highly effective in treating only a 
subset of TNBC patients. Discovery of the c-Abl/TAp73 mechanism of cisplatin induced 
cell death in TNBC lead to the assessment of ∆Np63/TAp73 as a biomarker of cisplatin 
sensitivity in TNBC. However, this marker was not sufficient to identify sensitive 
patients, suggesting a need for more specific biomarkers. Our lab has identified miR-510 
to be overexpressed in human breast tissue samples, suggesting a role in breast cancer. 
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We have also shown that miR-510 plays an oncogenic role in breast cancer by 
upregulating proliferation, migration, invasion and colony formation. Our lab has 
validated Prdx1 to be a direct target of miR-510. Prdx1 has been shown to protect cells 
from cisplatin and also inhibit the tyrosine kinase c-Abl. Therefore we wanted to 
determine the efficacy of miR-510 as a biomarker of cisplatin sensitivity and elucidate 
the mechanism of this sensitivity.  
Screening cisplatin cytotoxicity and miR-510 expression in TNBC cells lines 
reveals a positive correlation between miR-510 expression and cisplatin sensitivity. The 
GOF study shows that overexpression of miR-510 could sensitize resistance TNBC cell 
lines to cisplatin. On the other hand, LOF study demonstrates that inhibition of miR-510 
of sensitive cell lines leads to increased resistance. This data suggests that miR-510 
directly modulates cisplatin sensitivity in TNBC and may serve as a potential biomarker. 
MicroRNAs are ideal biomarkers in cancer as they regulate many processes in cancer 
development and progression and are also stable in biological fluids. Therefore, we 
wanted to explore the potential of miR-510 as a non-invasive biomarker. Analysis of 
serum samples from the in vivo study reveals that miR-510 could be detected by qPCR. 
Since serum expression of miR-510 is not indicative of its activity in the tumor, we then 
quantified miR-510 expression of tumor samples and compared them to miR-510 
expression of matched serum samples. A positive correlation of miR-510 levels in 
matched tumor and serum samples suggests that serum expression of miR-510 is 
indicative of its expression in tumor samples. To determine whether serum expression 
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of miR-510 is relevant in human breast cancer, we quantified miR-510 in serum samples 
of human breast cancer patients. The data demonstrates that varying levels of miR-510 
can be detected in human samples as well.  
We then went on to explore the mechanism of miR-510 mediated cisplatin 
sensitivity. IHC analysis of in vivo tumors suggests that miR-510 mediated sensitivity 
may not be through decreased proliferation or increased cleaved-caspase 3 dependent 
apoptosis. Prdx1 IHC analysis, along with matched tumor miR-510 expression, shows 
that miR-510 negatively regulates Prdx1 in an in vivo setting. This also suggests that 
negative regulation of Prdx1 may play a role in miR-510 mediated cisplatin sensitivity. 
The Prdx1 rescue experiments found that the mechanism of miR-510 mediated 
sensitivity is dependent upon the negative regulation of Prdx1. To explore further 
downstream of this pathway, we then explored TAp73 activity. We found that 
overexpression of miR-510 leads to increased phosphorylation of TAp73 upon cisplatin 
treatment, which possibly leads to the stabilization and accumulation of TAp73. We 
have also shown that this leads to dissociation of TAp73 from its repressor ∆Np63. To 
provide further evidence of activation of TAp73 pathway, our qPCR analysis reveals a 
higher level of downstream pro-apoptotic genes, PUMA and NOXA in miR-510 cells 
treated with cisplatin. Cumulatively, our data demonstrates that miR-510 is a potential, 
non-invasive biomarker of cisplatin sensitivity in TNBC. We also show this mechanism 
of sensitivity is attributed to, at least in part, the negative regulation of Prdx1 and the 




Next steps in this project will be to continue to explore the efficacy of miR-510 as 
a biomarker of cisplatin sensitivity in TNBC. Screening additional TNBC cell lines will 
provide a comprehensive overview of miR-510 role in this heterogeneous subtype of 
breast cancer. Screening cell lines harboring BRCA1 mutations, like SUM149, will help 
determine if miR-510 could mediate cisplatin sensitivity independent of BRCA1 status. 
Repeating GOF and LOF studies in additional cell lines will also strengthen the data to 
support our hypothesis. Further mechanistic studies are required to continue elucidating 
the mechanism behind miR-510 mediated cisplatin sensitivity. Although we believe 
miR-510 mediated activation of TAp73 is through c-Abl, there still lacks definitive 
evidence. c-Abl inhibition studies with imatinib (tyrosine kinases inhibitor) or c-Abl 
shRNA will determine whether miR-510 mediated cisplatin sensitivity is dependent on 
the kinase activity of c-Abl. Various studies have demonstrated the role of MAPK, 
particularly JNK, to interact with proteins in this pathway. Uncovering the roles of these 
proteins in this pathway as potential synergistic signaling pathways or feedback 
mechanisms will help in revealing the complex process of miR-510 mediated cisplatin 
sensitivity. Understanding the mechanism of this sensitivity will allow for more effective 
utilization of miR-510 as a biomarker. In a collaboration with Amelia Zelnack (EMORY 
University) using clinical trial (NCT01194869) samples, we also want to demonstrate 
that miR-510 is an effective marker of cisplatin sensitivity in human TNBC patients. This 
clinical trial is investigating the efficacy of preoperative sorafenib (tyrosine kinase 
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inhibitor) and cisplatin, followed by paclitaxel (taxane chemotherapy) for early stage 
TNBC. Analysis of the patient serum samples and their treatment response will allow us 
to determine if miR-510 has potential utility as a biomarker of response to platinum 
chemotherapy agents. There are limitations utilizing this trial as proof of concept, as the 
combination therapy will not provide as clear evidence as a trial with single agent 
cisplatin. However, it could provide partial evidence that miR-510 is a feasible 
biomarker in the clinic and possibly lead to single-agent cisplatin trials here at MUSC in 
the future. To test the efficacy of miR-510 as a non-invasive biomarker, more studies are 
required to standardize serum collection, processing, normalization and interpretation; 
which are problems that hamper the clinical application of miRNA biomarker studies 
[76].  
Study Significance  
The goal of this investigation is to assess the utility of miR-510 expression as a 
potential treatment choice marker in TNBC. Our lab has previous demonstrated the 
oncogenic role of miR-510 in breast cancer, suggesting that miR-510 is better suited as a 
biomarker rather than a therapeutic target. This will aid in identifying patients who 
would be responsive to platinum chemotherapy agents and spare those patients who 
would be non-responders from unnecessary treatment; and as a direct consequence, 
increase the number of patients who respond well to first line treatment. Maximizing 
response to first-line chemotherapy is crucial as it is associated with increased overall 
survival in TNBC. TNBC is known to relapse early and improving treatment outcome is 
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important, as TNBC that do not recur in 5 years are considered to be cured. Utilization 
of miR-510 as a clinical biomarker is feasible as miRNA diagnostics test are 
commercially available (Prometheus Laboratories Inc). This research has great 
translational significance, potentially providing a means to improved survival disparity 
of the aggressive subtype of triple negative breast cancer.    
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